WO2014076490A1 - Process for preparing nucleoside prodrugs - Google Patents

Process for preparing nucleoside prodrugs Download PDF

Info

Publication number
WO2014076490A1
WO2014076490A1 PCT/GB2013/053018 GB2013053018W WO2014076490A1 WO 2014076490 A1 WO2014076490 A1 WO 2014076490A1 GB 2013053018 W GB2013053018 W GB 2013053018W WO 2014076490 A1 WO2014076490 A1 WO 2014076490A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
product
formula
moiety
Prior art date
Application number
PCT/GB2013/053018
Other languages
French (fr)
Inventor
Christopher Mcguigan
Fabrizio PERTUSATI
Original Assignee
University College Cardiff Consultants Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2014076490(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Priority to EP17169878.0A priority Critical patent/EP3235824B1/en
Priority to CA2891266A priority patent/CA2891266C/en
Priority to AU2013346515A priority patent/AU2013346515B2/en
Priority to EP13792965.9A priority patent/EP2920192B1/en
Priority to CN201380069952.2A priority patent/CN104903339A/en
Priority to BR112015011155-6A priority patent/BR112015011155B1/en
Priority to PL17169878T priority patent/PL3235824T3/en
Priority to US14/442,987 priority patent/US10005810B2/en
Priority to KR1020157015861A priority patent/KR20150103669A/en
Application filed by University College Cardiff Consultants Limited filed Critical University College Cardiff Consultants Limited
Priority to ES13792965.9T priority patent/ES2618732T3/en
Priority to EA201590955A priority patent/EA028871B1/en
Priority to NZ708177A priority patent/NZ708177A/en
Priority to IN4090DEN2015 priority patent/IN2015DN04090A/en
Priority to SG11201503750YA priority patent/SG11201503750YA/en
Priority to MX2015006195A priority patent/MX2015006195A/en
Priority to JP2015542357A priority patent/JP2016506371A/en
Publication of WO2014076490A1 publication Critical patent/WO2014076490A1/en
Priority to IL238792A priority patent/IL238792A/en
Priority to PH12015501090A priority patent/PH12015501090A1/en
Priority to HK15111437.1A priority patent/HK1210784A1/en
Priority to US15/994,378 priority patent/US11040997B2/en
Priority to CY20191100503T priority patent/CY1121663T1/en
Priority to US17/323,367 priority patent/US20220033433A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Definitions

  • the present invention relates to a process for preparing chemical compounds and to the chemical compounds prepared by the present process.
  • Administering to a patient a racemic mixture of a chiral pharmaceutical compound may mean that only one enantiomer of the compound can partake in the desired therapeutic reaction.
  • the synthesis of a chiral pharmaceutical compound can include additional and expensive steps performed on the racemic mixture to enrich the end product with the desired enantiomer. Such steps include, for example, chiral chromatography. In past processes, expenditure is thus necessarily incurred, either due to the preparation of a racemic mixture only a part of which is usefully pharmaceutically active or due to the additional process steps performed to remove at least some of the non-desired enantiomer from the racemic mixture prior to administration of the compound to a patient in need thereof.
  • the present invention provides a process that meets this need.
  • the present invention also provides the compounds provided by the present process and pharmaceutical compositions comprising such compounds.
  • the present process provides a process for preparing phosphoramidates of nucleosides where a desired enantiomer, having regard to the asymmetric chiral centre of the phosphorus atom P, is provided in an enriched amount.
  • R/S system of nomenclature of enantiomers is followed.
  • a chiral centre having regard to the phosphorus atom P is labeled Rp or Sp according to a system in which the substituents on the atom P are each assigned a priority based on atomic number, according to the Cahn-Ingold-Prelog priority rules (CIP).
  • CIP Cahn-Ingold-Prelog priority rules
  • the CIP rules allocate the lowest priority to the direct substituent on the chiral centre P having the lowest atomic number. In the case of a phosphoramidate, this subs tuent is N. The P centre is then orientated so that the N substituent is pointed away from the viewer. The atoms or next nearest atoms, if present, to the three O atoms directly linked to P are then considered, according to the CIP rules.
  • Ar is selected from C 6 . 3 oaryl and C 6 - 3 oheteroaryl, each of which is optionally substituted;
  • Ri, R 2 and R 3 are, independently, selected from H and the group consisting of C 1-20 alkyl, C 2 - 20 alkenyl, C 1-20 alkoxy, C ⁇ oalkoxyd. ⁇ alkyl, C ⁇ oalkoxyCe-soaryl, C 2 . 20 alkynyl, C 3-2 - cycloalkylC 6 - 3 oaryl, C 6 . 30 aryloxy and C 5 . 2 oheterocyclyl, any of which is optionally substituted; ⁇ and T 2 are linked together and together are selected from the group consisting of:
  • T 3 is selected from the group consisting of H and -COOCi- 6 alkyl and T 4 and T 5 are, independently, selected from the group consisting of H, F, CI, Br, I, OH and methyl (CH 3 ); and B is selected from the group consisting of a heterocyclic moiety derived from purine and a heterocyclic moiety derived from pyrimidine; comprising the steps of:
  • T l5 T 2 and B have the same meanings set out with respect to Formula I;
  • step (ii) admixing the product of step (i) with a compound of Formula III, wherein Formula III is: where Ar, R l5 R 2 and R 3 have the same meanings set out with respect to Formula I, wherein step (ii) takes place in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.
  • step (i) an ethereal solvent is employed in step (i).
  • the catalyst is admixed with the nucleoside compound of Formula II, prior to the dissolution of the compound of Formula II in the solvent of step (i).
  • the phosphorochloridate of Formula III is dissolved in a solvent.
  • the solvent is suitably selected from the group consisting of an ethereal solvent, acetonitrile and mixtures thereof.
  • the solvent is an ethereal solvent.
  • a solvent employed to dissolve the phosphoramidate of Formula III
  • it may be the same as or different to the solvent employed to dissolve the compound of Formula II in step (i).
  • it is the same.
  • it is the same and is an ethereal solvent.
  • the reaction of the present process is suitably performed under an inert atmosphere, for example of argon or nitrogen.
  • the reaction of the present process is sukably carried out under a dry atmosphere.
  • the reaction of the present process is suitably carried out with stirring.
  • the present process can be carried out at room temperature. Room temperature is defined herein to be between 15 and 25°C.
  • the reaction of the present process can be monitored by HPLC (High Performance/Pressure Liquid Chromatography).
  • the desired compound is separated.
  • solvent can be evaporated under reduced pressure and the residue can be purified by column chromatography.
  • additional steps such as chiral column chromatography can be performed on the product of the above process to enhance yet further the Rp:Sp ratio of the phosphoramidate nucleoside produced.
  • additional steps can comprise standard techniques known to those skilled in the art, for example, use of a chiral HPLC column.
  • the present process involves a mechanism in which the metal salt interacts with the nucleoside of Formula II such that the nucleoside is directed to react with the phosphorochloridate of Formula III in a selected diastereospecific manner.
  • the O ring atom in the sugar moiety of the nucleoside of Formula II is required to assist this mechanism.
  • mixtures of Rp and Sp enantiomers can be prepared in which the ratio of Rp:Sp is not equal to 1.
  • mixtures of phosphoramidated nucleosides can be prepared by the present process where the ratio of Rp:Sp is more than 1, suitably more than 2.5, more suitably more than 5, even more suitably more than 7.5.
  • the upper limit sought to the ratio of R P :Sp is 100:0.
  • the upper limit to the ratio of Rp:Sp available by use of the above process may be less than 100:0, but very usefully it could be as high as 20:1.
  • additional process steps can be undertaken, for example chiral column chromatography, to enhance yet further the ratio of Rp:Sp of enantiomers produced by the present process, so as to achieve, if desired, a ratio of 100:0.
  • use of the present invention may produce a mixture of phosphoramidated nucleosides where the ratio of Rp:Sp is less than 1, suitably less than 2.5, more suitably less than 5, even more suitably less than 7.5.
  • the lower limit sought to the ratio of Rp:Sp is 0:100.
  • the lower limit to the ratio of Rp:Sp available by use of the above process may be more than 0:100, but very usefully it could be as low as 1 :20.
  • additional process steps can be undertaken, for example chiral chromatography, to enhance yet further the ratio of Rp:Sp of enantiomers produced by the present process, so as to achieve, if desired, a ratio of 0:100.
  • the present process is applicable to the phosphorochloridates of Formula III. It is believed, however, that the present process is particularly suitable for use with phosphorochloridates where one or more of the moieties Ar, R l5 R 2 and R 3 comprise moieties that are relatively large sterically.
  • Such phosphorochloridates are believed to interact favorably with compounds of Formula II, especially where, as mentioned above, B has an NH moiety as part of its aromatic ring system or, where B is derived from a purine moiety has, at position 2, an exocyclic heteroatom, such as a substituent comprising NH 2 , NHC 1-6 alkyl, OH, OC 1-6 alkyl, SH, SC 1-6 alkyl or CI, preferably NH 2 , directly linked to its aromatic ring system.
  • B has an NH moiety as part of its aromatic ring system or, where B is derived from a purine moiety has, at position 2, an exocyclic heteroatom, such as a substituent comprising NH 2 , NHC 1-6 alkyl, OH, OC 1-6 alkyl, SH, SC 1-6 alkyl or CI, preferably NH 2 , directly linked to its aromatic ring system.
  • Particularly preferred compounds of Formula III for use in the present process include those where Ar is naphthyl, one of Ri and R 2 is a secondary or tertiary alkyl group and/or R3 is either a tertiary alkyl group or benzyl. Particularly preferred are compounds of Formula III where, in combination, Ar is naphthyl, one of R ⁇ and R 2 is tertiary alkyl and R 3 is tertiary alkyl.
  • Ar can alternatively be phenyl, especially where one of R ⁇ and R 2 is a secondary or tertiary alkyl group, especially a tertiary alkyl group, and R 3 is a tertiary alkyl group or is benzyl, especially a tertiary alkyl group.
  • R ⁇ and R 2 is a secondary or tertiary alkyl group, especially a tertiary alkyl group
  • R 3 is a tertiary alkyl group or is benzyl, especially a tertiary alkyl group.
  • Particularly preferred are compounds of Formula III where, in combination, Ar is phenyl, one of Ri and R 2 is tertiary alkyl and R 3 is tertiary alkyl.
  • Particularly preferred compounds of Formula III for use in the present process include those where Ar is naphthyl, one of R ⁇ and R 2 is a secondary or tertiary alkyl group and/or R 3 is a secondary alkyl group, a tertiary alkyl group or benzyl. Particularly preferred are compounds of Formula III where, in combination, Ar is naphthyl, one of R ⁇ and R 2 is tertiary alkyl and R 3 is tertiary alkyl.
  • Ar can alternatively be phenyl, especially where one of R ⁇ and R 2 is a secondary or tertiary alkyl group, especially a tertiary alkyl group, and R 3 is a secondary alkyl group, a tertiary alkyl group or is benzyl, especially a tertiary alkyl group.
  • R ⁇ and R 2 is a secondary or tertiary alkyl group, especially a tertiary alkyl group
  • R 3 is a secondary alkyl group, a tertiary alkyl group or is benzyl, especially a tertiary alkyl group.
  • Particularly preferred are compounds of Formula III where, in combination, Ar is phenyl, one of Ri and R 2 is tertiary alkyl and R 3 is tertiary alkyl.
  • preferred compounds of Formula III have, in any combination, one of Ri and R 2 as a primary alkyl and one of R ⁇ and R 2 as hydrogen, as in for example L- alaninyl or D-alaninyl, R 3 as a secondary alkyl group, as in for example isopropyl, a tertiary alkyl group, as in for example neopentyl, or benzyl and Ar as naphthyl or phenyl.
  • Specific examples of preferred phosphorochloridates of Formula III include: naphthyl(oneopentyl-L-alaninyl)phosphorochloridate;
  • the phosphorochloridate is suitably employed in the present process in an amount that is the molar equivalent to the amount of the nucleoside of Formula II employed.
  • the amount of phosphorochloridate employed can be in the range of from 0.5 to 1.5, more suitably in the range of from 0.75 to 1.25 of the molar equivalent amount of the nucleoside of Formula II employed.
  • an amount of phosphorochloridate can be employed in the present process in an amount that is up to five times, preferably up to three times, the molar equivalent amount of the nucleoside of Formula II.
  • an "ethereal solvent' is employed for dissolving the phosphorochloridate, what is meant is an organic solvent that contains one or more, suitably up to and including three, more suitably up to and including two, -C-O-C moieties.
  • molecules of the solvent have a maximum C content of 12.
  • solvents include: DME, which is 1,2-dimethoxyethane (CH 3 -0-(CH 2 ) 2 -0-CH 3 ); THF, which is tetrahydrofuran (C 4 H 8 0); 1,4-dioxane, which is 1 ,4-dioxacyclohexane diethyl ether ( 1 ⁇ 2 ⁇ 5 -0- C 2 H 5 ); diphenyl ether (C 6 H 5 -0-C 6 H 5 ); anisole, which is methoxybenzene (C 6 H 5 -0-CH 3 ); and dimethoxybenzene (C6H 4 (OCH 3 ) 2 ).
  • a single ethereal solvent may be used or a mixture of ethereal solvents may be used.
  • the catalyst to be active in the present process must be the salt of a metal. "Oxides” are excluded from the definition of “salt, as used in the present application.
  • Particularly preferred metal salts for use as the catalyst are copper salts, both Cu(I) and Cu(II) salts being useful in the present process, although Cu(II) salts are preferred.
  • Particular preferred examples of copper salts that may be used in the present process include Cu(OTf) 2 , CuCl, CuBr, Cul, Cu(OAc) 2 .H 2 0 and anhydrous CuS0 4 .
  • Particular preferred examples of copper salts that may be used in the present process include Cu(OTf) 2 , CuCl, CuBr, Cul, Cu(OAc), Cu(OAc) 2 .H 2 0, anhydrous CuS0 4 and Cu(OC(0)CF 3 ) 2 .
  • Especially preferred is Cu(OTf) 2 .
  • Cu(OAc) is especially suitable where B is a heterocyclic moiety derived from pyrimidine, as, for example, present in gemcitabine.
  • OTf stands for the anion CF 3 SO 3 " , which is the anion of trifluoromethanesulphonic acid and "OAc” stands for the anion CH 3 CO 2 " .
  • Alternative catalysts that may be used in the present process are metal salts where the metal has an oxidation state of more than one and up to and including three.
  • metal salts of OTf where the metal has an oxidation state of more than one.
  • Preferred examples of such salts include Cu(OTf) 2 , Yb(OTf) 3 , Fe(OTf) 3 , and La(OTf) 3 , with Cu(OTf 2 being preferred.
  • metal salts suitable for use as catalysts in the present process where the metal has an oxidation state of more than one include tris(acetylacetonato)iron(III) (formula: Fe(C 5 H 7 0 2 )3) and bis(acetylacetonato)iron(II) (formula: Fe(C 5 H 7 0 2 ) 2 ).
  • the catalyst is suitably used in a concentration in the range of from 0.05 to 1.5 molar equivalent, more suitably in the range of from 0.05 to 1.25 molar equivalent, even more suitably in the range of from 0.05 to 0.5 molar equivalent, even more suitably in the range of from 0.075 to 0.25 molar equivalent, even more suitably at a molar equivalent amount of 0.1, relative to the molar amount of the phosphorochloridate of Formula III employed in the present process.
  • the metal salt of the catalyst must include one or more anions.
  • suitable anions include CF 3 S0 3 " , CI “ , Br “ , ⁇ , CH 3 C0 2 " , S0 4 2" or CF 3 C0 2 ' .
  • a further example of a suitable anion is the acetylacetonato anion having the formula (0-CH(CH 3 )-CH 2 -CH(CH 3 )-0) ⁇
  • the metal component of the metal salt may be present either unco-ordinated, as exemplified above, or in the form of a complex where a metal cation component is co-ordinated with one or more ligands.
  • ligands may be bound to the metal cation component in the complex.
  • the metal cation component in the complex is preferably a copper cation component.
  • suitable ligands include MeCN and C 6 3 ⁇ 4.
  • suitable complexes include (Cu(MeCN) 4 ) + and (CuC 6 H ) + .
  • suitable metal salts that include the metal component in the form of a complex where the metal cation component is co-ordinated with one or more ligands include Cu(MeCN)4-CF 3 S0 3 and Cu(C 6 H 6 ) CF 3 S0 3 .
  • the metal component of the present catalyst is unco-ordinated and the metal component of the catalyst is not bound to one or more ligands. It is believed that the metal component of the present catalyst is more suitably unco-ordinated in order to act as a catalyst. Although the inventors do not wish to be bound by any theory, it is believed that metal components that are not bound to ligands can more readily interact with the O ring atom of the sugar moiety of the nucleoside and also, possibly, the NH moiety and/or the exocyclic heteroatom moiety of B, as discussed above.
  • an organic solvent is meant that contains one or more, up to and including, suitably, three, more suitably up to and including two, C-O-C moieties.
  • molecules of the ethereal solvent have a maximum C content of 12.
  • solvents include: DME, which is 1,2-dimethoxyethane (CH 3 -0-(CH 2 ) 2 -0- CH 3 ); THF, which is tetrahydrofuran (C 4 H 8 0); 1,4-dioxane, which is 1,4-dioxacyclohexane (C 4 H 8 0 2 ); diethyl ether (C 2 H 5 -0-C 2 H 5 ); anisole, which is methoxybenzene (C 6 H 5 -0-CH 3 ); and dimethoxybenzene (C6H 4 (CH 3 ) 2 ).
  • DME 1,2-dimethoxyethane
  • THF which is tetrahydrofuran
  • 1,4-dioxane 1,4-dioxacyclohexane
  • diethyl ether C 2 H 5 -0-C 2 H 5
  • anisole which is methoxybenzene (C 6 H 5 -0-CH 3 ); and
  • the base employed in step (i) of the present process should preferably be selected from the group consisting of NR4R5R6, where R , R 5 and 3 ⁇ 4 are selected, independently, from the group consisting of Ci -3 alkyl and H, provided that at least two of R4, R 5 and R6 are, independently, C 1-3 alkyl.
  • Suitable examples of such bases include: DIPEA, which is N,N-diisopropylethylamine ((/-Pr) 2 NEt); (i-Pr) 2 NH; and N(Et) 3 .
  • DIPEA and ( -Pr) 2 NH are preferred.
  • DIPEA, ( -Pr) 2 NH and N(Et) 3 are preferred.
  • the base DBU which is 1 ,8-diazabicyclo[5.4.0]undec-7-ene (C 9 H 16 N 2 ), may be employed.
  • the base employed in the present process is suitably present in an amount between 1 and 2 molar equivalents, more suitably in an amount between 1.25 and 1.75 molar equivalents, compared to the amount of phosphorochloridate employed. Most suitably, the base is employed in an amount of 1.5 molar equivalents of the amount of phosphorochloridate employed.
  • Tj and T 2 suitably comprise T3, T 4 and T 5 , as set out above, and, more suitably, comprise T 4 being the same as T 5 , for example, T 4 and T 5 can both be F or H, or alternatively, more suitably, T 4 and T 5 are not the same, for example, T 4 is CH 3 or H and T 5 is OH or F, particularly preferred examples being T 4 as CH 3 in combination with T 5 as OH, T 4 as H in combination with T 5 as F and T 4 as H in combination with T 5 as OH.
  • T 4 and T 5 is OH.
  • T 3 is H or C0 2 tBu, especially in combination with any of the immediately preceding combinations disclosed for T 4 and T5.
  • Particularly preferred combinations of T3, T 4 and T5 include: T 3 as H, T 4 as CH 3 and T 5 as OH; T3 as H, T 4 as H and T 5 as H; T3 as H, T 4 as H and T 5 as F; T 3 as H, T 4 as H and T 5 as OH; T3 as H, T 4 as OH and T5 as H; and T3 as C0 2 tBu, T 4 as F and T 5 as F.
  • T3 is not H
  • each of T 4 and T 5 is not F and B is not 4-amino-pyrimidine-2(lH)-one where the Nl atom of the pyrimidine derived moiety is linked directly with the CI atom of the sugar moiety.
  • T 3 is not H
  • each of T 4 and T 5 is not F and B is not 4-amino-pyrimidine-2(lH)-one where the Nl atom of the pyrimidine derived moiety is linked directly with the CI atom of the sugar moiety, in combination with the catalyst being Cu(OTf) 2 or any of Cu(OTf) 2 , Yb(OTf) 3 , Fe(OTf) 3 and La(OTf) 3 .
  • the present process can be employed to prepare a compound of Formula I where B is derived from a purine moiety or a pyrimidine moiety.
  • B is derived from a purine moiety
  • B of the nucleoside moiety of the compound of Formula II is as follows, where the N atom marked with * links directly to the CI atom of the sugar moiety:
  • each of X and Z is, independently, selected from H, OH, F, CI, Br, I, OC 1-6 alkyl, Q. 6 alkyl and NR 7 Rg, where each of R 7 and R 8 is, independently, selected from H and C].
  • 6 alkyl; and Y is selected from H, OH, OC 1-6 alkyl, SH, SC 1-6 alkyl, F, CI, Br, I, C 1-6 alkyl, C 2 . 8 alkynyl, NR RKI where each of R and R 10 is, independently, selected from H and C 1-6 alkyl.
  • X is selected from OCH 3 , NH 2 , NH(cyclicC 3 H 5 ), H, OH, F, CI; Y is selected from H, NH 2 , OH, F, CI and C 2-8 alkynyl; and Z is H.
  • Preferred compounds of Formula II include those where B is derived from purine and: X is OCH3, Y is NH 2 and Z is H; X is NH 2 , Y is H and Z is H; X is NH(cyclicC 3 H 5 ), Y is NH 2 and Z is H; X is NH 2 , Y is CI and Z is H; X is CI, Y is NH 2 and Z is H; X is NH 2 , Y is F and Z is H; and X is NH 2 , Y is C 2 . 8 alkynyl, preferably C 2 . 6 alkynyl, and Z is H. Where Y is C 2 .
  • B is derived from a pyrimidine moiety
  • B of the nucleoside moiety of the compound of Formula II is as follows, where the N atom marked with * links directly with the CI atom of the sugar moiety:
  • Compounds of Formula II particularly suitable for use in the present process can comprise compounds that have the preferred respective options for B derived from a purine moiety or from a pyrimidine moiety, as set out above, in combination with any of the preferred options for Tj and T 2 , as set out above.
  • Specific examples of compounds of Formula II suitable for use in the present process include, where the common name is given first, followed, in brackets, by the IUPAC name the following nucleosides:
  • 2',3'iPrA (2',3'-isopropylidene adenosine); gemcitabine (4-amino- 1 -(2-deoxy-2,2-difluoro-P-D-erythro- pentofiiranosyl)pyrimidin-2( 1 H)-one);
  • FUDR (5-Fluoro- 1 -[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]- 1 H- pyrimidine-2,4-dione); d4T (l-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine- 2,4(lH,3H)-dione); cladribine (5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol); isocladribine (2-amino-6-chloro-2' -deoxyguanosine); fludarabine ([(2R,3R,4S,5 )-5-(6-amino-2-fluoro-purin-9-yl)-3,4-dihydroxy- oxolan-2-yl]methoxyphosphonic acid); clofarabine (5-(6-amin
  • R] and R 2 are selected such that they correspond to the side chains of a natural amino acid.
  • Ri and R 2 is Me and one of Ri and R 2 is H, such that the C atom bearing R] and R 2 has chirality L as in natural alanine.
  • R 3 is alkyl, more preferably R 3 is selected from the group consisting of methyl, ethyl, 2-propyl, 2-butyl, -CH 2 -C(CH 3 ) 3 and benzyl, even more preferably R 3 is selected from the group consisting of methyl (-CH 3 ) and benzyl (-CH 2 C 6 H 5 ).
  • C6- 3 oheteroaryl for Ar is meant a six to thirty membered aromatic ring system that can contain one or more heteroatoms in the ring system, as further defined below.
  • Preferred Ar entities include phenyl, pyridyl, naphthyl and quinolyl, each of which may be substituted or unsubstituted. Especially preferred as Ar is naphthyl, particularly unsubstituted naphthyl. Pyridyl is -C5NH .
  • Each of Ar, R 1? R 2 and R 3 can be substituted with one, two, three, four, five or more substituents independently selected from the group comprising electron donating and electron withdrawing moieties.
  • Substituents on Ar can be located ortho-, meta-, para- or otherwise on the aromatic groups.
  • Substituents on Ar are suitably, independently, selected from the group consisting of hydroxy, acyl, acyloxy, nitro, amino, carboxyl, Ci. 6 esters, C 1-6 aldehyde, cyano, C ⁇ . alkylamino, C 1-6 dialkylamino, thiol, chloro, bromo, fluoro, iodo, C ⁇ aUcyl, C 2-6 alkenyl, d. 6 alkoxy-C 1-6 alkyl, C 5 .
  • Substituents on Ri, R 2 and R 3 are, independently, selected from the group consisting of hydroxy, acyl, acyloxy, nitro, amino, amido, carboxy, C ⁇ esters, C 1-6 aldehyde, cyano, Ci. 6alkylamino, C 1-6 dialkylamino, thiol, chloro, bromo, fluoro, iodo, C 5-7 cycloalkyl, C 5-7 cycloalkenyl, C 5 .
  • Rj and R 2 are suitably independently selected from the group consisting of H, C M oalkyl, C 2- ioalkenyl, C2-i 0 alkoxyC 1-10 alkyl, C M oalkoxyCe-ioaryl, C2-i 0 alkynyl, C 3-2 ocycloalkyl, C 3 . 20 cycloalkenyl, C 4-20 cycloalkynyl, and C 5 . 10 heterocyclyl.
  • Ri and/or R2 are preferably a side chain of a natural amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, lysine, arginine, histidine, aspartic acid, glutamic acid, asparagines, glutamine, cysteine and methionine.
  • a natural amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, lysine, arginine, histidine, aspartic acid, glutamic acid, asparagines, glutamine, cysteine and methionine.
  • the stereochemistry at the asymmetric centre -CR 1 R 2 corresponds to an L- amino acid.
  • the stereochemistry at the asymmetric centre -CR ⁇ can, however, correspond to a D-amino acid.
  • mixtures of compounds can be employed having asymmetric centres corresponding to L and D amino acids.
  • the present invention is not, however, limited to compounds having a moiety corresponding to a naturally occurring amino acid.
  • the moiety RaOCOCR ⁇ NH- corresponds to or is derived from a non-naturally occurring amino acid.
  • R 3 is suitably selected from the group consisting of H, C 1-10 alkyl, C 2- ioalkenyl, Ci- !
  • oalkoxy Ci.ioalkoxyC oalkyl, CMoalkoxyCe-ioaryl, C 2-10 alkynyl, C 3-20 cycloalkyl, C 3-20 cycloalkenyl, C 4-2 ocycloalkynyl, and Cs ⁇ oheterocyclyl.
  • R 3 is more suitably selected from the group consisting of H, C 1-10 alkyl, C 3 . 20 cycloalkyl and benzyl.
  • alkyl refers to a straight or branched saturated monovalent cyclic or acyclic hydrocarbon radical, having the number of carbon atoms as indicated (or where not indicated, an acyclic alkyl group preferably has 1-20, more preferably 1-6, more preferably 1-4 carbon atoms and a cyclic alkyl group preferably has 3-20, preferably 3-10, more preferably 3-7 carbon atoms), optionally substituted with one, two, three or more substituents independently selected from the group set out above with respect to substituents that may be present on R 1 ( R 2 and R 3 .
  • suitable alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, octyl, nonyl and dodecyl.
  • tertiary alkyl radicals including t-butyl and -CH 2 - C(CH 3 ) 3 .
  • suitable alkenyl groups include vinyl, propenyl, butenyl, pentenyl and hexenyl.
  • alkynyl refers to a straight or branched unsaturated monovalent acyclic or cyclic hydrocarbon radical having one or more triple C ⁇ C bonds and having the number of carbon atoms as indicated (or where not indicated, an acyclic alkynyl group preferably has 2-20, more preferably 2-6, more preferably 2-4 carbon atoms and a cyclic alkynyl group preferably has 7-20, more preferably 8-20 carbon atoms), optionally substituted with one, two, three or more substituents, independently, selected from the group set out above with respect to substituents that may be present on R l5 R 2 and R 3 .
  • alkoxy refers to the group alkyl-O-, where alkyl is as defined herein and where the alkyl moiety may optionally be substituted by one, two, three or more substituents as set out above for alkyl.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec- butoxy, n-pentoxy, n-hexoxy and 1,2-dimethylbutoxy.
  • aryloxy refers to the group aryl-O-, where aryl is as defined herein and where the aryl moiety may optionally be substituted by one, two, three or more substituents as set out above with respect to the group Ar.
  • alkoxyalkyl refers to an alkyl group having an alkoxy substituent. Binding is through the alkyl group.
  • the alkyl moiety and the alkoxy moiety are as defined herein with respect to the definitions of alkyl and alkoxy, respectively.
  • the alkoxy and alkyl moieties may each be substituted by one, two, three or more substituents as set out above with regard to the definition of alkyl.
  • alkoxyaryl refers to an aryl group having an alkoxy substituent. Binding is through the aryl group.
  • the alkoxy moiety and the aryl moiety are as defined herein with respect to the definitions of alkoxy and aryl, respectively.
  • the alkoxy and aryl moieties may each be substituted by one, two, three or more substituents, as defined herein with regard to the definitions of alkoxy and aryl, respectively.
  • cycloalkylaryl refers to an aryl group having a cyclic alkyl substituted. Binding is through the aryl group.
  • the cycloalkyl moiety and the aryl moiety are as defined herein with respect to the definitions of cycloalkyl and aryl, respectively.
  • the cycloalkyl moiety and the aryl moiety may each be optionally substituted by one, two, three or more substituents as set out herein with regard to the definitions of alkyl and aryl, respectively.
  • aryl refers to a monovalent unsaturated aromatic carbocyclic radical having one, two, three, four, five or six rings, preferably one, two or three rings, which may be fused or bicyclic.
  • An aryl group may optionally be substituted by one, two, three or more substituents as set out above with respect to optional substituents that may be present on the group Ar.
  • Preferred aryl groups are: an aromatic monocyclic ring containing 6 carbon atoms; an aromatic bicyclic or fused ring system containing 7, 8, 9 or 10 carbon atoms; or an aromatic tricyclic ring system containing 10, 11, 12, 13 or 14 carbon atoms.
  • Non-limiting examples of aryl include phenyl and naphthyl.
  • Preferred substituent groups are independently selected from hydroxy, acyl, acyloxy, nitro, amino, carboxyl, cyano, Ci- 6alkylamino, Q-edialkylamino, thiol, chloro, bromo, fluoro, iodo, SO3H, SH, SR' wherein R' is independently selected from the same groups as Ri.
  • C 6 - 3 oheteroaryl refers to a monovalent unsaturated aromatic heterocyclic 6 to 30 membered radical having one, two, three, four, five or six aromatic rings, preferably one, two or three aromatic rings, which may be fused or bicyclic, and having contained within the aromatic ring at least one and up to six, suitably up to three, heteroatoms, independently, selected from the group consisting of N, O and S. Available carbon atoms and/or heteroatoms in the heteroaryl ring system may be substituted on the ring with one or more substituents as set out above with respect to the substituents that may be present on the group Ar.
  • Preferred heteroaryl groups are: an aromatic monocyclic ring system containing six members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; an aromatic monocyclic ring having six members of which one, two or three members are a N atom; an aromatic bicyclic or fused ring having nine members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; or an aromatic bicyclic ring having ten members of which one, two or three members are a N atom. Examples include, and are not limited to, pyridyl and quinolyl.
  • heterocyclyl refers to a saturated or partially unsaturated heterocyclic ring system having one, two, three, four, five or six rings, preferably one, two or three rings, which may be fused or bicyclic, and having contained within the ring or rings at least one and up to six, suitably up to three, members selected, independently, from the group consisting of N, O and S.
  • the prefix “Cs -20 “ or “C5 -10 " used before heterocyclyl means, respectively, a five to twenty or a five to ten membered ring system at least one of which members is selected from the group consisting of N, O and S.
  • Preferred heterocyclyl systems are: a monocyclic ring system having five members of which at least one member is a N, O or S atom and which optionally contains one additional O atom or one, two or three additional N atoms; a monocyclic ring having six members of which one, two or three members are a N atom; a bicyclic ring system having nine members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; or a bicyclic ring system having ten members of which one, two or three members are a N atom.
  • Examples include, and are not limited to, pyrrolinyl, pyrrolidinyl, 1,3- dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl or piperazinyl.
  • heteroatom substituents are selected from oxygen, nitrogen, sulphur and halogen (F, CI, Br and I).
  • halogen F, CI, Br and I
  • the ring(s) is substituted with one or more heteroatoms, preferably there are 1, 2, 3 or 4 heteroatom substituents selected from the group consisting of oxygen, nitrogen and/or halogen.
  • Preferred substituent groups are, independently, selected from hydroxy, acyl, acyloxy, nitro, amino, carboxyl, cyano, Q-ealkylamino, C 1- dialkylamino, thiol, chloro, bromo, fluoro, iodo, SO3H, SH and SR' wherein R' is, independently, selected from the same groups as Ri.
  • Compounds prepared by the process of the present invention may be useful the therapeutic treatment of homo sapiens and animals, preferably homo sapiens, in the treatment of cancer, including the treatment of solid cancers such as breast, colon or prostate cancer and the treatment of leukaemia, which is a malignancy of blood, and as anti- viral agents with respect to e.g. HIV, HBV, HCV and CMV.
  • a particular example of a compound that can usefully be prepared by the process of the present invention is 2-amino-6-methoxy-9-(2'-C- rnethyl-P-D-ribofuranosyl)purine 5'-0-[a-naphthyl-(2,2-dimethylpropoxy-L-ananinyl)] phosphate, which is useful in the treatment of HCV.
  • Particular, examples of such compounds are the phosphoramidated nucleosides corresponding to the products of Examples 1 to 4, 6, 7, 10 to 14, 16 to 21, 23, 26 to 27, 29 to 37, 39 to 42 and 44 to 46 below, either in the respective Rp:Sp ratios illustrated in the Examples below and in ratios of Rp:Sp obtained by variants of the exemplified processes that comply with the process of the present invention.
  • a compound produced by the present process, or pharmaceutically acceptable salt or ester or solvate of said compound can be used to preparing pharmaceutical compositions by combining the compound, or salt or ester or solvate thereof, with one or more pharmaceutical acceptable excipients, diluents or carriers.
  • the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts.”
  • FDA approved pharmaceutical acceptable salt forms include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
  • Pharmaceutically acceptable acidic/anionic salts include, and are not limited to acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, diphospate, polygalacturonate, salicylate, stearate,
  • ester derivatives in which one or more free hydroxy groups are esterified in the form of a pharmaceutically acceptable ester are particularly prodrug esters that may be convertible by solvolysis under physiological conditions to the compounds of the present invention having free hydroxy groups.
  • compositions incorporating compounds produced by the present process, or salts, esters or solvates thereof may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • These pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee- making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen.
  • the compound having formula I or a pharmaceutical composition comprising a compound having formula I according to the present invention can be administered to a patient, which may be homo sapiens or animal, by any suitable means.
  • a patient which may be homo sapiens or animal
  • Such medicaments can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
  • the pharmaceutical compositions will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
  • Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives.
  • suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while cornstarch and alginic acid are suitable disintegrating agents.
  • Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc.
  • the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
  • Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin.
  • Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
  • the compounds of the invention may also be presented as liposome formulations.
  • a suitable dose will be in the range of 0.1 to 300 mg per kilogram body weight of the recipient per day.
  • a preferred lower dose is 0.5 mg per kilogrm body weight of recpient per day, a more preferred lower dose is 1 mg per kilogram body weight of recipient per day.
  • a suitable dose is preferably in the range of 1 to 50 mg per kilogram body weight per day, and more preferably in the range of 1 to 10 mg per kilogram body weight per day.
  • the desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.
  • Fig. 1 shows the HPLC spectrum of the product of Example 1
  • Fig. 2 shows the HPLC spectrum of the product of Example 42
  • Fig. 3 shows the reaction scheme and HPLC spectrum of the product of Example 43;
  • Fig. 4 shows the reaction scheme and HPLC spectrum of the product of Example 44;
  • Fig. 5 shows the reaction scheme and HPLC spectrum of the product of Example 45;
  • Fig. 6 shows the reaction scheme and HPLC spectrum of the product of Example 46;
  • Fig. 7 shows the HPLC spectrum of the product of Example 47; and
  • Fig. 8 shows the HPLC spectrum of the product of Example 48.
  • a dry round bottomed flask is charged with a magnetic stirring bar, 2'-C methyl-6-O- methylguanosine (2'CMe60MeG) (106.0 mg, 0.34 mmol.) and catalytic amount of copper (II) trifluoromethane sulfonate (12.32 mg, 0.34 mmol, 0.1 equiv.).
  • the flask is sealed with a rubber septum and purged with dry argon.
  • Anhydrous 1,2-dimethoxyethane (DME, 10 mL) is added via syringe and the resulting light blue solution is stirred at room temperature for 5-10 minutes.
  • Example 5 is a reference example.
  • Examples 29 to 35 Using the experimental procedure set out above, gemcitabine (100 mg) was employed as the nucleoside and naphthyl(isopropyl-L-alaninyl)phosphorochoridate (1 molar equiv) was employed as the phosphorochloridate.
  • the catalyst (MX), base and solvent were employed, as set out in the reaction scheme and in Table 7 below.
  • Example 29 employed 10 ml THF and 2 ml MeCN. Table 7 gives, for each example, the total yield and the ratio of Rp:Sp enantiomers achieved.
  • AA indicates the amino acid moiety corresponding to - CNHCR ⁇ COz-
  • Examples 36 to 42 Using the experimental procedure set out above, 2'deoxy-2'fluorouridine (100 mg) was employed as the nucleoside and naphthyl(iso-propyl-L-alaninyl)phosphorochloridate (1 molar equiv) was employed as the phosphorochloridate.
  • the catalyst, base and solvent for each example are set out in Table 8 below. In each case, the reaction took place at room temperature under nitrogen and for 24 hours. Examples 38 and 41 are reference examples.
  • nelarabine was employed as the nucleoside (lOOmg) and naphthyl(oneopentyl-L-alaninyl)phosphorochloridate (1 molar equiv) was employed as the phosphorochloridate.
  • Cu(OTf) 2 0.1 equiv was employed as the catalyst.
  • NEt 3 1.5 equiv was employed as the base and 10ml of THF were employed as the solvent. The reaction took place at room temperature under argon for 12 hours.
  • the phosphoramidated nelarabine reaction product was produced in a yield of 80% and comprised a ratio of Rp:Sp enantiomers of 3.6: 1.
  • reaction scheme for the diastereoselective synthesis of protide via metal catalysis with respect to nelarabine of the present example and the HPLC of the reaction product are set out in Fig. 3.
  • A/B in Fig. 3 refers to Rp/Sp.
  • clofarabine (100 mg) was employed as the nucleoside and naphthyl(oneopentyl-L-alaninyl)phosphorochloridate (1 molar equiv) was employed as the phosphorochloridate.
  • Cu(OTf)2 (0.1 equiv) was employed as the catalyst.
  • NEt 3 (1.5 equiv) was employed as the base and 10 ml of THF were employed as the solvent.
  • the reaction took place at room temperature under argon for 12 hours.
  • the phosphoramidated clofarabine reaction product was achieved in a yield of about 40% and comprised a ratio of Rp:Sp enantiomers of 1 : 1.5.
  • reaction scheme for the diastereoselective synthesis of protide via metal catalysis with respect to clofarabine of the present example and the HPLC spectrum of the reaction product are set out in Fig. 4.
  • A/B in Fig. refers to Rp/Sp.
  • Example 45 Using the experimental procedure set out above, 2'deoxy-2'fluorouridine (100 mg) was employed as the nucleoside and naphthyl(iso-propyl-L-alaninyl)phosphochloridate (1 molar equiv.) was employed as the phosphorochloridate. 0.2 molar equivalents of Cu(OC(0)CF 3 )2 were used as the catalyst. 1.5 molar equivalents of NEt 3 were employed as the base. 10 ml of DME were employed as the solvent. The reaction took place at room temperature under nitrogen for 12 hours.
  • the phosphoramidated 2'deoxy-2'fluoruridine reaction product was produced in a yield of 35% and comprised a ratio of Rp:Sp enantiomers of 1 :5.3.
  • Boc gemcitabine 100 mg was employed as the nucleoside and naphthyl(iso-propyl-L-alaninyl)phosphorochloridate (1 molar equiv.) was employed as phosphorochloridate.
  • 0.2 molar equivalents of Cu(OC)(0)CF 3 ) 2 were used as the catalyst.
  • NEt 3 1.5 equiv were employed as the base.
  • 50 ml DME were employed as the solvent. The reaction took place under nitrogen at room temperature for 24 hours.
  • the phosphoramidated gemcitabine reaction product was produced in a yield of 9% and comprised a ratio of Rp:Sp enantiomers of 1 :9.
  • Example 47 Using the experimental procedure set out above, 4-amino-l-((2R,3R,4R5R)-3-fluoro-4- hydroxy-5-(hydroxymemyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(l H)-one (100 mg) was employed as the nucleoside and 2 molar equivalents of phenyl(isopropyl-L- alaninyl)phosphorochloridate (150 mg) were employed as the phosphorochloridate. 0.5 molar equivalents of Cu(CF 3 C0 2 ) 2 (30 mg) were employed as the catalyst. 1.5 molar equivalents of DIPEA (55 microlitres) were employed as the base and 10 ml of DME were employed as the solvent. The reaction took place at room temperature for 24 hours.
  • the phosphoramidated reaction product was produced in a yield of 20% and comprised ratio of Rp:Sp enantiomers of 1 :66.
  • the phosphoramidated reaction product was produced in yield of 45% and comprised ratio of Rp:Sp enantiomers of 3:1.

Abstract

A process for preparing phosphoramidates of nucleosides where a desired enantiomer, having regard to the asymmetric chiral centre of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Ciu Fe, La and Yb.

Description

PROCESS FOR PREPARING NUCLEOSIDE PRODRUGS
The present invention relates to a process for preparing chemical compounds and to the chemical compounds prepared by the present process.
The chemical synthesis of a chiral compound usually results in a racemic mixture of the compound in which R and S enantiomers are present in equal amounts.
Many biologically active systems, however, involve specific enantiomers or diastereoisomers of chiral compounds. Such chiral biological systems may react differently to the different enantiomers or diasteroisomers of a pharmaceutical chiral compound.
Administering to a patient a racemic mixture of a chiral pharmaceutical compound may mean that only one enantiomer of the compound can partake in the desired therapeutic reaction. The synthesis of a chiral pharmaceutical compound can include additional and expensive steps performed on the racemic mixture to enrich the end product with the desired enantiomer. Such steps include, for example, chiral chromatography. In past processes, expenditure is thus necessarily incurred, either due to the preparation of a racemic mixture only a part of which is usefully pharmaceutically active or due to the additional process steps performed to remove at least some of the non-desired enantiomer from the racemic mixture prior to administration of the compound to a patient in need thereof.
A need thus exists to provide a more cost effective process for preparing a chiral compound for therapeutic use where the compound comprises at least an enriched portion of a desired enantiomer.
The present invention provides a process that meets this need.
The present invention also provides the compounds provided by the present process and pharmaceutical compositions comprising such compounds. In particular, the present process provides a process for preparing phosphoramidates of nucleosides where a desired enantiomer, having regard to the asymmetric chiral centre of the phosphorus atom P, is provided in an enriched amount. Throughout the present application, the R/S system of nomenclature of enantiomers is followed. A chiral centre having regard to the phosphorus atom P is labeled Rp or Sp according to a system in which the substituents on the atom P are each assigned a priority based on atomic number, according to the Cahn-Ingold-Prelog priority rules (CIP). Reference concerning the CIP rules is made to "Advanced Organic Chemistry by J. March published by John Wiley & Sons (2007) and IUPAC Rules for the Nomenclature of Organic Chemistry, Section E, Stereochemistry (1974). The CIP rules allocate the lowest priority to the direct substituent on the chiral centre P having the lowest atomic number. In the case of a phosphoramidate, this subs tuent is N. The P centre is then orientated so that the N substituent is pointed away from the viewer. The atoms or next nearest atoms, if present, to the three O atoms directly linked to P are then considered, according to the CIP rules. If these atoms decrease in atomic number when viewed in a clockwise direction, the enantiomer is labeled Rp. If these atoms decrease in atomic number in a counterclockwise direction, the enantiomer is labeled Sp. According to the present invention there is provided a process for the preparation of a compound of Formula I, wherein Formula I is:
Figure imgf000003_0001
wherein:
Ar is selected from C6.3oaryl and C6-3oheteroaryl, each of which is optionally substituted;
Ri, R2 and R3 are, independently, selected from H and the group consisting of C1-20alkyl, C2-20alkenyl, C1-20alkoxy, C^oalkoxyd.^alkyl, C^oalkoxyCe-soaryl, C2.20alkynyl, C3-2- cycloalkylC6-3oaryl, C6.30aryloxy and C5.2oheterocyclyl, any of which is optionally substituted; Τι and T2 are linked together and together are selected from the group consisting of:
Figure imgf000004_0001
where T3 is selected from the group consisting of H and -COOCi-6alkyl and T4 and T5 are, independently, selected from the group consisting of H, F, CI, Br, I, OH and methyl (CH3); and B is selected from the group consisting of a heterocyclic moiety derived from purine and a heterocyclic moiety derived from pyrimidine; comprising the steps of:
(i) dissolving a compound of Formula II in a solvent selected from the group consisting of an ethereal solvent, acetonitrile and mixtures thereof and admixing the dissolved compound of Formula II with a base, wherein Formula II is:
Figure imgf000004_0002
where Tl5 T2 and B have the same meanings set out with respect to Formula I;
(ii) admixing the product of step (i) with a compound of Formula III, wherein Formula III is:
Figure imgf000005_0001
where Ar, Rl5 R2 and R3 have the same meanings set out with respect to Formula I, wherein step (ii) takes place in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.
Suitably, an ethereal solvent is employed in step (i). Suitably, the catalyst is admixed with the nucleoside compound of Formula II, prior to the dissolution of the compound of Formula II in the solvent of step (i).
Suitably, the phosphorochloridate of Formula III is dissolved in a solvent. The solvent is suitably selected from the group consisting of an ethereal solvent, acetonitrile and mixtures thereof. Suitably, the solvent is an ethereal solvent.
Where a solvent is employed to dissolve the phosphoramidate of Formula III, it may be the same as or different to the solvent employed to dissolve the compound of Formula II in step (i). Suitably, it is the same. Suitably, it is the same and is an ethereal solvent.
The reaction of the present process is suitably performed under an inert atmosphere, for example of argon or nitrogen.
The reaction of the present process is sukably carried out under a dry atmosphere.
The reaction of the present process is suitably carried out with stirring. The present process can be carried out at room temperature. Room temperature is defined herein to be between 15 and 25°C.
The reaction of the present process can be monitored by HPLC (High Performance/Pressure Liquid Chromatography).
When the reaction of the present process is complete, the desired compound is separated. For example, solvent can be evaporated under reduced pressure and the residue can be purified by column chromatography.
If desired, additional steps, such as chiral column chromatography can be performed on the product of the above process to enhance yet further the Rp:Sp ratio of the phosphoramidate nucleoside produced. Such additional steps can comprise standard techniques known to those skilled in the art, for example, use of a chiral HPLC column.
Where compounds produced by the present process have two or more chiral centers, they may additionally exist as diastereoisomers, which, if desired, can be separated by conventional techniques such as preparative chromatography. Any or all of the process steps disclosed herein relating to the present invention may be employed in any combination, as desired.
Although the inventors do not wish to be bound by any theory, it is believed that the present process involves a mechanism in which the metal salt interacts with the nucleoside of Formula II such that the nucleoside is directed to react with the phosphorochloridate of Formula III in a selected diastereospecific manner. In particular, it is believed that the O ring atom in the sugar moiety of the nucleoside of Formula II is required to assist this mechanism. It is also believed, although the inventors do not wish to be bound by any theory, that this mechanism is assisted by the presence of an NH moiety, where the N is a heteroatom in an aromatic ring moiety of B and/or, where B consists of a heterocyclic moiety derived from purine, by the presence of an exocyclic heteroatom selected from the group consisting of N, O, S and CI, preferably N, directly linked to position 2 of the aromatic ring moiety of B, for example, by the presence at position 2 of a substituent selected from NH2, NHC1-6alkyl, OH, OCi-6alkyl, SH, SC1-6alkyl or CI, and is preferably NH2.
By use of the present invention, mixtures of Rp and Sp enantiomers can be prepared in which the ratio of Rp:Sp is not equal to 1.
Suitably, mixtures of phosphoramidated nucleosides can be prepared by the present process where the ratio of Rp:Sp is more than 1, suitably more than 2.5, more suitably more than 5, even more suitably more than 7.5. Ideally the upper limit sought to the ratio of RP:Sp is 100:0. Practically, the upper limit to the ratio of Rp:Sp available by use of the above process may be less than 100:0, but very usefully it could be as high as 20:1. If desired, additional process steps can be undertaken, for example chiral column chromatography, to enhance yet further the ratio of Rp:Sp of enantiomers produced by the present process, so as to achieve, if desired, a ratio of 100:0.
Alternatively, use of the present invention may produce a mixture of phosphoramidated nucleosides where the ratio of Rp:Sp is less than 1, suitably less than 2.5, more suitably less than 5, even more suitably less than 7.5. Ideally the lower limit sought to the ratio of Rp:Sp is 0:100. Practically, the lower limit to the ratio of Rp:Sp available by use of the above process may be more than 0:100, but very usefully it could be as low as 1 :20. If desired, additional process steps can be undertaken, for example chiral chromatography, to enhance yet further the ratio of Rp:Sp of enantiomers produced by the present process, so as to achieve, if desired, a ratio of 0:100. The present process is applicable to the phosphorochloridates of Formula III. It is believed, however, that the present process is particularly suitable for use with phosphorochloridates where one or more of the moieties Ar, Rl5 R2 and R3 comprise moieties that are relatively large sterically. Such phosphorochloridates are believed to interact favorably with compounds of Formula II, especially where, as mentioned above, B has an NH moiety as part of its aromatic ring system or, where B is derived from a purine moiety has, at position 2, an exocyclic heteroatom, such as a substituent comprising NH2, NHC1-6 alkyl, OH, OC1-6 alkyl, SH, SC1-6alkyl or CI, preferably NH2, directly linked to its aromatic ring system. Particularly preferred compounds of Formula III for use in the present process include those where Ar is naphthyl, one of Ri and R2 is a secondary or tertiary alkyl group and/or R3 is either a tertiary alkyl group or benzyl. Particularly preferred are compounds of Formula III where, in combination, Ar is naphthyl, one of R\ and R2 is tertiary alkyl and R3 is tertiary alkyl. Suitably, Ar can alternatively be phenyl, especially where one of R\ and R2 is a secondary or tertiary alkyl group, especially a tertiary alkyl group, and R3 is a tertiary alkyl group or is benzyl, especially a tertiary alkyl group. Particularly preferred are compounds of Formula III where, in combination, Ar is phenyl, one of Ri and R2 is tertiary alkyl and R3 is tertiary alkyl. Particularly preferred compounds of Formula III for use in the present process include those where Ar is naphthyl, one of R\ and R2 is a secondary or tertiary alkyl group and/or R3 is a secondary alkyl group, a tertiary alkyl group or benzyl. Particularly preferred are compounds of Formula III where, in combination, Ar is naphthyl, one of R\ and R2 is tertiary alkyl and R3 is tertiary alkyl. Suitably, Ar can alternatively be phenyl, especially where one of R\ and R2 is a secondary or tertiary alkyl group, especially a tertiary alkyl group, and R3 is a secondary alkyl group, a tertiary alkyl group or is benzyl, especially a tertiary alkyl group. Particularly preferred are compounds of Formula III where, in combination, Ar is phenyl, one of Ri and R2 is tertiary alkyl and R3 is tertiary alkyl. Alternatively, preferred compounds of Formula III have, in any combination, one of Ri and R2 as a primary alkyl and one of R\ and R2 as hydrogen, as in for example L- alaninyl or D-alaninyl, R3 as a secondary alkyl group, as in for example isopropyl, a tertiary alkyl group, as in for example neopentyl, or benzyl and Ar as naphthyl or phenyl. Specific examples of preferred phosphorochloridates of Formula III include: naphthyl(oneopentyl-L-alaninyl)phosphorochloridate;
phenyl(oneopentyl-L-alaninyl)phosphorochloridate;
naphthyl(benzyl-D-alaninyl)phosphorochloridate;
naphthyl(benzyl-L-valinyl)phosphorochloridate;
phenyl(benzyl-L-alaninyl)phosphorochloridate;
naphthyl(isopropyl-L-alaninyl)phosphorochloridate; and
phenyl(isopropyl-L-alaninyl)phosphorochloridate.
The phosphorochloridate is suitably employed in the present process in an amount that is the molar equivalent to the amount of the nucleoside of Formula II employed. In practice, if desired, the amount of phosphorochloridate employed can be in the range of from 0.5 to 1.5, more suitably in the range of from 0.75 to 1.25 of the molar equivalent amount of the nucleoside of Formula II employed. If desired, an amount of phosphorochloridate can be employed in the present process in an amount that is up to five times, preferably up to three times, the molar equivalent amount of the nucleoside of Formula II.
Where an "ethereal solvent' is employed for dissolving the phosphorochloridate, what is meant is an organic solvent that contains one or more, suitably up to and including three, more suitably up to and including two, -C-O-C moieties. Suitably, molecules of the solvent have a maximum C content of 12. Preferred examples of such solvents include: DME, which is 1,2-dimethoxyethane (CH3-0-(CH2)2-0-CH3); THF, which is tetrahydrofuran (C4H80); 1,4-dioxane, which is 1 ,4-dioxacyclohexane
Figure imgf000009_0001
diethyl ether ( ½Η5-0- C2H5); diphenyl ether (C6H5-0-C6H5); anisole, which is methoxybenzene (C6H5-0-CH3); and dimethoxybenzene (C6H4(OCH3)2). A single ethereal solvent may be used or a mixture of ethereal solvents may be used.
The catalyst to be active in the present process must be the salt of a metal. "Oxides" are excluded from the definition of "salt, as used in the present application.
Particularly preferred metal salts for use as the catalyst are copper salts, both Cu(I) and Cu(II) salts being useful in the present process, although Cu(II) salts are preferred. Particular preferred examples of copper salts that may be used in the present process include Cu(OTf)2, CuCl, CuBr, Cul, Cu(OAc)2.H20 and anhydrous CuS04. Particular preferred examples of copper salts that may be used in the present process include Cu(OTf)2, CuCl, CuBr, Cul, Cu(OAc), Cu(OAc)2.H20, anhydrous CuS04 and Cu(OC(0)CF3)2. Especially preferred is Cu(OTf)2. Also especially preferred is Cu(OAc). Cu(OAc) is especially suitable where B is a heterocyclic moiety derived from pyrimidine, as, for example, present in gemcitabine.
Throughout the present application, "OTf stands for the anion CF3SO3 ", which is the anion of trifluoromethanesulphonic acid and "OAc" stands for the anion CH3CO2 ". Alternative catalysts that may be used in the present process are metal salts where the metal has an oxidation state of more than one and up to and including three. Especially preferred are metal salts of OTf where the metal has an oxidation state of more than one. Preferred examples of such salts include Cu(OTf)2, Yb(OTf)3, Fe(OTf)3, and La(OTf)3, with Cu(OTf 2 being preferred. Other preferred metal salts suitable for use as catalysts in the present process where the metal has an oxidation state of more than one include tris(acetylacetonato)iron(III) (formula: Fe(C5H702)3) and bis(acetylacetonato)iron(II) (formula: Fe(C5H702)2). The catalyst is suitably used in a concentration in the range of from 0.05 to 1.5 molar equivalent, more suitably in the range of from 0.05 to 1.25 molar equivalent, even more suitably in the range of from 0.05 to 0.5 molar equivalent, even more suitably in the range of from 0.075 to 0.25 molar equivalent, even more suitably at a molar equivalent amount of 0.1, relative to the molar amount of the phosphorochloridate of Formula III employed in the present process.
The metal salt of the catalyst must include one or more anions. Examples of suitable anions include CF3S03 ", CI", Br", Γ, CH3C02 ", S04 2" or CF3C02 '. A further example of a suitable anion is the acetylacetonato anion having the formula (0-CH(CH3)-CH2-CH(CH3)-0)\ The metal component of the metal salt may be present either unco-ordinated, as exemplified above, or in the form of a complex where a metal cation component is co-ordinated with one or more ligands. Suitably 1, 2, 3 or 4 ligands may be bound to the metal cation component in the complex. The metal cation component in the complex is preferably a copper cation component. Examples of suitable ligands include MeCN and C6¾. Examples of suitable complexes include (Cu(MeCN)4)+ and (CuC6H )+. Examples of suitable metal salts that include the metal component in the form of a complex where the metal cation component is co-ordinated with one or more ligands include Cu(MeCN)4-CF3S03 and Cu(C6H6) CF3S03. Suitably, the metal component of the present catalyst is unco-ordinated and the metal component of the catalyst is not bound to one or more ligands. It is believed that the metal component of the present catalyst is more suitably unco-ordinated in order to act as a catalyst. Although the inventors do not wish to be bound by any theory, it is believed that metal components that are not bound to ligands can more readily interact with the O ring atom of the sugar moiety of the nucleoside and also, possibly, the NH moiety and/or the exocyclic heteroatom moiety of B, as discussed above.
Where the solvent employed in step (i) of the present process to dissolve the nucleoside of Formula II is an ethereal solvent, an organic solvent is meant that contains one or more, up to and including, suitably, three, more suitably up to and including two, C-O-C moieties. Suitably molecules of the ethereal solvent have a maximum C content of 12. Preferred examples of such solvents include: DME, which is 1,2-dimethoxyethane (CH3-0-(CH2)2-0- CH3); THF, which is tetrahydrofuran (C4H80); 1,4-dioxane, which is 1,4-dioxacyclohexane (C4H802); diethyl ether (C2H5-0-C2H5); anisole, which is methoxybenzene (C6H5-0-CH3); and dimethoxybenzene (C6H4(CH3)2). A single ethereal solvent may be used or mixture of ethereal solvents may be used.
It is believed that the base employed in step (i) of the present process should preferably be selected from the group consisting of NR4R5R6, where R , R5 and ¾ are selected, independently, from the group consisting of Ci-3 alkyl and H, provided that at least two of R4, R5 and R6 are, independently, C1-3 alkyl. Suitable examples of such bases include: DIPEA, which is N,N-diisopropylethylamine ((/-Pr)2NEt); (i-Pr)2NH; and N(Et)3. DIPEA and ( -Pr)2NH are preferred. DIPEA, ( -Pr)2NH and N(Et)3 are preferred. Alternatively the base DBU, which is 1 ,8-diazabicyclo[5.4.0]undec-7-ene (C9H16N2), may be employed.
The base employed in the present process is suitably present in an amount between 1 and 2 molar equivalents, more suitably in an amount between 1.25 and 1.75 molar equivalents, compared to the amount of phosphorochloridate employed. Most suitably, the base is employed in an amount of 1.5 molar equivalents of the amount of phosphorochloridate employed.
With respect to Ti and T2 in Formulae I and II, Tj and T2 suitably comprise T3, T4 and T5, as set out above, and, more suitably, comprise T4 being the same as T5, for example, T4 and T5 can both be F or H, or alternatively, more suitably, T4 and T5 are not the same, for example, T4 is CH3 or H and T5 is OH or F, particularly preferred examples being T4 as CH3 in combination with T5 as OH, T4 as H in combination with T5 as F and T4 as H in combination with T5 as OH. Suitably, if present, only one of T4 and T5 is OH. Suitably, T3 is H or C02tBu, especially in combination with any of the immediately preceding combinations disclosed for T4 and T5. Particularly preferred combinations of T3, T4 and T5 include: T3 as H, T4 as CH3 and T5 as OH; T3 as H, T4 as H and T5 as H; T3 as H, T4 as H and T5 as F; T3 as H, T4 as H and T5 as OH; T3 as H, T4 as OH and T5 as H; and T3 as C02tBu, T4 as F and T5 as F. Suitably, together T3 is not H, each of T4 and T5 is not F and B is not 4-amino-pyrimidine-2(lH)-one where the Nl atom of the pyrimidine derived moiety is linked directly with the CI atom of the sugar moiety. Suitably, together T3 is not H, each of T4 and T5 is not F and B is not 4-amino-pyrimidine-2(lH)-one where the Nl atom of the pyrimidine derived moiety is linked directly with the CI atom of the sugar moiety, in combination with the catalyst being Cu(OTf)2 or any of Cu(OTf)2, Yb(OTf)3, Fe(OTf)3 and La(OTf)3.
The present process can be employed to prepare a compound of Formula I where B is derived from a purine moiety or a pyrimidine moiety.
Where B is derived from a purine moiety, suitably B of the nucleoside moiety of the compound of Formula II is as follows, where the N atom marked with * links directly to the CI atom of the sugar moiety:
Figure imgf000012_0001
where each of X and Z is, independently, selected from H, OH, F, CI, Br, I, OC1-6alkyl, Q. 6alkyl and NR7Rg, where each of R7 and R8 is, independently, selected from H and C]. 6alkyl; and Y is selected from H, OH, OC1-6alkyl, SH, SC1-6alkyl, F, CI, Br, I, C1-6alkyl, C2. 8alkynyl, NR RKI where each of R and R10 is, independently, selected from H and C1-6 alkyl. More suitably, in combination, X is selected from OCH3, NH2, NH(cyclicC3H5), H, OH, F, CI; Y is selected from H, NH2, OH, F, CI and C2-8alkynyl; and Z is H. Preferred compounds of Formula II include those where B is derived from purine and: X is OCH3, Y is NH2 and Z is H; X is NH2, Y is H and Z is H; X is NH(cyclicC3H5), Y is NH2 and Z is H; X is NH2, Y is CI and Z is H; X is CI, Y is NH2 and Z is H; X is NH2, Y is F and Z is H; and X is NH2, Y is C2.8alkynyl, preferably C2.6alkynyl, and Z is H. Where Y is C2.8alkynyl, preferably Y is linear C2-6alkynyl and preferably Y contains one triple C≡C bond at the alpha position. Where B is derived from a pyrimidine moiety, suitably B of the nucleoside moiety of the compound of Formula II is as follows, where the N atom marked with * links directly with the CI atom of the sugar moiety:
Figure imgf000013_0001
where U is selected from the group consisting of H, C^alkyl, F, CI, Br and I; and n is 0 or 1, wherein when n is 0, V is -NH2 and a double bond exists between position 3 and position 4, and when n is 1, V is =0. Preferred compounds of Formula II include those where B is derived from pyrimidine and have in combination: U as H and V as NH2; U as F and V as =0; and U as C¾ and V as =0. Compounds of Formula II particularly suitable for use in the present process can comprise compounds that have the preferred respective options for B derived from a purine moiety or from a pyrimidine moiety, as set out above, in combination with any of the preferred options for Tj and T2, as set out above. Specific examples of compounds of Formula II suitable for use in the present process include, where the common name is given first, followed, in brackets, by the IUPAC name the following nucleosides:
2'CMe60MeG (2-(2-amino-6-methoxy-9H-purin-9-yl)-5-(hydroxymethyl)-3- methyloxolane-3,4-diol); nelarabine (2R,3S,4R,5R-2-(2-amino-6-methoxy-purin-9-yl)-5-
(hydroxymethyl)oxolane-3 ,4-diol);
2',3'iPrA (2',3'-isopropylidene adenosine); gemcitabine (4-amino- 1 -(2-deoxy-2,2-difluoro-P-D-erythro- pentofiiranosyl)pyrimidin-2( 1 H)-one);
3 ' -boc gemcitabine (4-amino- 1 -(2-deoxy-2,2-difluoro-3 ' -tert-buthoxycarbonyl- -D- erythro-pentoiuranosyl)pyrimidin-2(lH)-one));
FUDR (5-Fluoro- 1 -[4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]- 1 H- pyrimidine-2,4-dione); d4T (l-((2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)-5-methylpyrimidine- 2,4(lH,3H)-dione); cladribine (5-(6-amino-2-chloro-purin-9-yl)-2-(hydroxymethyl)oxolan-3-ol); isocladribine (2-amino-6-chloro-2' -deoxyguanosine); fludarabine ([(2R,3R,4S,5 )-5-(6-amino-2-fluoro-purin-9-yl)-3,4-dihydroxy- oxolan-2-yl]methoxyphosphonic acid); clofarabine (5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3- ol); fluorodeoxyuridine (2 ' -fluoro-2 ' -deoxyuridine); cytarabine (4-amino-l-[(2R,3S,^R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2- yl] pyrimidin-2-one); cytidine (4-amino- 1 - [3 ,4-dihydroxy-5-(hydroxymethyl)tetrahydrofiiran-2-yl] pyrimidin-2-one); and
2'-deoxy-2'-fluoro-2'-Cmethylc tidine (4-amino- l-((2R,3R,4R,5R)-3-fluoro-4- hydroxy-5-(hydroxymemyl)-3-memyltetrahydror½an-2-yl)pyrimidin-2(lH)-one). Preferably R] and R2 are selected such that they correspond to the side chains of a natural amino acid.
Preferably one of Ri and R2 is Me and one of Ri and R2 is H, such that the C atom bearing R] and R2 has chirality L as in natural alanine.
Preferably R3 is alkyl, more preferably R3 is selected from the group consisting of methyl, ethyl, 2-propyl, 2-butyl, -CH2-C(CH3)3 and benzyl, even more preferably R3 is selected from the group consisting of methyl (-CH3) and benzyl (-CH2C6H5).
By "C6-3oheteroaryl" for Ar is meant a six to thirty membered aromatic ring system that can contain one or more heteroatoms in the ring system, as further defined below.
Preferred Ar entities include phenyl, pyridyl, naphthyl and quinolyl, each of which may be substituted or unsubstituted. Especially preferred as Ar is naphthyl, particularly unsubstituted naphthyl. Pyridyl is -C5NH .
Each of Ar, R1? R2 and R3 can be substituted with one, two, three, four, five or more substituents independently selected from the group comprising electron donating and electron withdrawing moieties.
Substituents on Ar can be located ortho-, meta-, para- or otherwise on the aromatic groups. Substituents on Ar are suitably, independently, selected from the group consisting of hydroxy, acyl, acyloxy, nitro, amino, carboxyl, Ci.6esters, C1-6aldehyde, cyano, C\. alkylamino, C1-6dialkylamino, thiol, chloro, bromo, fluoro, iodo, C^aUcyl, C2-6alkenyl, d. 6alkoxy-C1-6alkyl,
Figure imgf000015_0001
C5. 7cycloalkenyl, C5.-7cycloaU.ynyl, Cs-narylQ-ealkyl, Ci^alkylCs-naryl, Cs-naryl, C1-6 fluoroalkyl, C2-6fluoroalkenyl, S03H, SH and SR' wherein R' is independently selected from the same group as set out herein for Ri. Each substituent can be substituted by any other substituent. Preferred substituents on Ar are F, CI, CF3 and N02. Where Ar is phenyl, the preferred position for a single substituent, which is preferably F, CI, CF3 or N02, is para-. Substituents on Ri, R2 and R3 are, independently, selected from the group consisting of hydroxy, acyl, acyloxy, nitro, amino, amido, carboxy, C^esters, C1-6aldehyde, cyano, Ci. 6alkylamino, C1-6dialkylamino, thiol, chloro, bromo, fluoro, iodo, C5-7cycloalkyl, C5-7 cycloalkenyl, C5.7cycloalkynyl, C5.naryl, Cs-iiaryld-ealkyl, C5-20heterocyclyl, S03H, SH and SR' wherein R' is independently selected from the same group set out herein for R\. Each substituent can be substituted by any other substituent.
Rj and R2 are suitably independently selected from the group consisting of H, CMoalkyl, C2-ioalkenyl, C2-i0alkoxyC1-10alkyl, CMoalkoxyCe-ioaryl, C2-i0alkynyl, C3-2ocycloalkyl, C3. 20cycloalkenyl, C4-20cycloalkynyl, and C5.10heterocyclyl.
Ri and/or R2 are preferably a side chain of a natural amino acid selected from the group consisting of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, lysine, arginine, histidine, aspartic acid, glutamic acid, asparagines, glutamine, cysteine and methionine. Specifically, Ri and/or R2 are preferably selected from the group consisting of H, CH3, -CH(CH3)2, -CH2CH(CH3)2, - CH(CH3)(CH2CH3), -CH2Ph, -CH2Ph-OH, -CH2SH, -CH2CH2SCH3, -CH2OH, - CH(CH3)(OH), -CH2CH2CH2CH2NH , -CH2CH2CH2NHC(=NH2+)NH2, -CH2C(0)0- , -CH2CH2C(0)0-, -CH2C(0)NH2, -CH2CH2C(0)NH2,
Figure imgf000016_0001
Preferably, the stereochemistry at the asymmetric centre -CR1R2 corresponds to an L- amino acid. The stereochemistry at the asymmetric centre -CR^ can, however, correspond to a D-amino acid. Alternatively, mixtures of compounds can be employed having asymmetric centres corresponding to L and D amino acids.
The present invention is not, however, limited to compounds having a moiety corresponding to a naturally occurring amino acid. The present invention specifically includes compounds having a moiety which corresponds to a non-naturally occurring amino acid, such as, for example, those where R1=R2=alkyl, or, where together with the C atom to which they are attached, Rj and R2 provide a cyclic moiety. Preferably with respect to the compound of formula I, the moiety RaOCOCR^NH- corresponds to or is derived from a non-naturally occurring amino acid. R3 is suitably selected from the group consisting of H, C1-10alkyl, C2-ioalkenyl, Ci-!oalkoxy, Ci.ioalkoxyC oalkyl, CMoalkoxyCe-ioaryl, C2-10alkynyl, C3-20cycloalkyl, C3-20cycloalkenyl, C4-2ocycloalkynyl, and Cs^oheterocyclyl.
R3 is more suitably selected from the group consisting of H, C1-10alkyl, C3.20cycloalkyl and benzyl.
All possible combinations for the preferred options for each of Ar, R1? R2, R3, T1} T2, T3, T4, T5 and B are herein disclosed, as are all such combinations together with all the preferred options set out herein for the process steps for performing the present process.
As used herein, the term "alkyl" refers to a straight or branched saturated monovalent cyclic or acyclic hydrocarbon radical, having the number of carbon atoms as indicated (or where not indicated, an acyclic alkyl group preferably has 1-20, more preferably 1-6, more preferably 1-4 carbon atoms and a cyclic alkyl group preferably has 3-20, preferably 3-10, more preferably 3-7 carbon atoms), optionally substituted with one, two, three or more substituents independently selected from the group set out above with respect to substituents that may be present on R1 ( R2 and R3. By way of non-limiting examples, suitable alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, octyl, nonyl and dodecyl. Especially preferred are tertiary alkyl radicals, including t-butyl and -CH2- C(CH3)3.
As used herein, the term "alkenyl" refers to a straight or branched unsaturated monovalent acyclic or cyclic hydrocarbon radical having one or more C=C double bonds and having the number of carbon atoms as indicated (or where not indicated, an acyclic alkenyl group preferably has 2-20, more preferably 2-6, more preferably 2-4 carbon atoms and a cyclic alkenyl group preferably has 4-20, more preferably 4-6 carbon atoms), optionally substituted with one, two, three or more substituents, independently, selected from the group set out above with respect to substituents that may be present on R1? R2 and R3. By way of non-limiting examples, suitable alkenyl groups include vinyl, propenyl, butenyl, pentenyl and hexenyl.
As used herein, the term "alkynyl" refers to a straight or branched unsaturated monovalent acyclic or cyclic hydrocarbon radical having one or more triple C≡C bonds and having the number of carbon atoms as indicated (or where not indicated, an acyclic alkynyl group preferably has 2-20, more preferably 2-6, more preferably 2-4 carbon atoms and a cyclic alkynyl group preferably has 7-20, more preferably 8-20 carbon atoms), optionally substituted with one, two, three or more substituents, independently, selected from the group set out above with respect to substituents that may be present on Rl5 R2 and R3.
As use herein, the term "alkoxy" refers to the group alkyl-O-, where alkyl is as defined herein and where the alkyl moiety may optionally be substituted by one, two, three or more substituents as set out above for alkyl. By way of non-limiting examples, suitable alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec- butoxy, n-pentoxy, n-hexoxy and 1,2-dimethylbutoxy.
As used herein, the term "aryloxy" refers to the group aryl-O-, where aryl is as defined herein and where the aryl moiety may optionally be substituted by one, two, three or more substituents as set out above with respect to the group Ar.
As used herein, the term "alkoxyalkyl" refers to an alkyl group having an alkoxy substituent. Binding is through the alkyl group. The alkyl moiety and the alkoxy moiety are as defined herein with respect to the definitions of alkyl and alkoxy, respectively. The alkoxy and alkyl moieties may each be substituted by one, two, three or more substituents as set out above with regard to the definition of alkyl.
As used herein, the term "alkoxyaryl" refers to an aryl group having an alkoxy substituent. Binding is through the aryl group. The alkoxy moiety and the aryl moiety are as defined herein with respect to the definitions of alkoxy and aryl, respectively. The alkoxy and aryl moieties may each be substituted by one, two, three or more substituents, as defined herein with regard to the definitions of alkoxy and aryl, respectively. As used herein, the term "cycloalkylaryl" refers to an aryl group having a cyclic alkyl substituted. Binding is through the aryl group. The cycloalkyl moiety and the aryl moiety are as defined herein with respect to the definitions of cycloalkyl and aryl, respectively. The cycloalkyl moiety and the aryl moiety may each be optionally substituted by one, two, three or more substituents as set out herein with regard to the definitions of alkyl and aryl, respectively.
As used herein, the term "aryl" refers to a monovalent unsaturated aromatic carbocyclic radical having one, two, three, four, five or six rings, preferably one, two or three rings, which may be fused or bicyclic. An aryl group may optionally be substituted by one, two, three or more substituents as set out above with respect to optional substituents that may be present on the group Ar. Preferred aryl groups are: an aromatic monocyclic ring containing 6 carbon atoms; an aromatic bicyclic or fused ring system containing 7, 8, 9 or 10 carbon atoms; or an aromatic tricyclic ring system containing 10, 11, 12, 13 or 14 carbon atoms. Non-limiting examples of aryl include phenyl and naphthyl. Preferred substituent groups are independently selected from hydroxy, acyl, acyloxy, nitro, amino, carboxyl, cyano, Ci- 6alkylamino, Q-edialkylamino, thiol, chloro, bromo, fluoro, iodo, SO3H, SH, SR' wherein R' is independently selected from the same groups as Ri. As used herein, the term "C6-3oheteroaryl" refers to a monovalent unsaturated aromatic heterocyclic 6 to 30 membered radical having one, two, three, four, five or six aromatic rings, preferably one, two or three aromatic rings, which may be fused or bicyclic, and having contained within the aromatic ring at least one and up to six, suitably up to three, heteroatoms, independently, selected from the group consisting of N, O and S. Available carbon atoms and/or heteroatoms in the heteroaryl ring system may be substituted on the ring with one or more substituents as set out above with respect to the substituents that may be present on the group Ar. Preferred heteroaryl groups are: an aromatic monocyclic ring system containing six members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; an aromatic monocyclic ring having six members of which one, two or three members are a N atom; an aromatic bicyclic or fused ring having nine members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; or an aromatic bicyclic ring having ten members of which one, two or three members are a N atom. Examples include, and are not limited to, pyridyl and quinolyl. As used herein, the term "heterocyclyl" refers to a saturated or partially unsaturated heterocyclic ring system having one, two, three, four, five or six rings, preferably one, two or three rings, which may be fused or bicyclic, and having contained within the ring or rings at least one and up to six, suitably up to three, members selected, independently, from the group consisting of N, O and S. The prefix "Cs-20" or "C5-10" used before heterocyclyl means, respectively, a five to twenty or a five to ten membered ring system at least one of which members is selected from the group consisting of N, O and S. Preferred heterocyclyl systems are: a monocyclic ring system having five members of which at least one member is a N, O or S atom and which optionally contains one additional O atom or one, two or three additional N atoms; a monocyclic ring having six members of which one, two or three members are a N atom; a bicyclic ring system having nine members of which at least one member is a N, O or S atom and which optionally contains one, two or three additional N atoms; or a bicyclic ring system having ten members of which one, two or three members are a N atom. Examples include, and are not limited to, pyrrolinyl, pyrrolidinyl, 1,3- dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl or piperazinyl.
Available carbon atoms and/or heteroatoms of the "heterocyclyl" ring systems described above may be substituted on the ring with one or more heteroatoms. Where the ring(s) is substituted with one or more heteroatoms, heteroatom substituents are selected from oxygen, nitrogen, sulphur and halogen (F, CI, Br and I). Where the ring(s) is substituted with one or more heteroatoms, preferably there are 1, 2, 3 or 4 heteroatom substituents selected from the group consisting of oxygen, nitrogen and/or halogen. Preferred substituent groups are, independently, selected from hydroxy, acyl, acyloxy, nitro, amino, carboxyl, cyano, Q-ealkylamino, C1- dialkylamino, thiol, chloro, bromo, fluoro, iodo, SO3H, SH and SR' wherein R' is, independently, selected from the same groups as Ri.
Compounds prepared by the process of the present invention may be useful the therapeutic treatment of homo sapiens and animals, preferably homo sapiens, in the treatment of cancer, including the treatment of solid cancers such as breast, colon or prostate cancer and the treatment of leukaemia, which is a malignancy of blood, and as anti- viral agents with respect to e.g. HIV, HBV, HCV and CMV. A particular example of a compound that can usefully be prepared by the process of the present invention is 2-amino-6-methoxy-9-(2'-C- rnethyl-P-D-ribofuranosyl)purine 5'-0-[a-naphthyl-(2,2-dimethylpropoxy-L-ananinyl)] phosphate, which is useful in the treatment of HCV.
Further specific examples of compounds of Formula I that can be suitably be prepared by the process of the present invention include phosphoramidated nucleosides prepared from compounds of Formula III which are any of the specific examples of the preferred phosphorochloridates listed above, in combination with compounds of Formula II which are any of the specific examples of the preferred nucleosides listed above. Particular, examples of such compounds are the phosphoramidated nucleosides corresponding to the products of Examples 1 to 4, 6, 7, 10 to 14, 16 to 21, 23, 26 to 27, 29 to 37, 39 to 42 and 44 to 46 below, either in the respective Rp:Sp ratios illustrated in the Examples below and in ratios of Rp:Sp obtained by variants of the exemplified processes that comply with the process of the present invention. An additional particular example of such compounds is isopropyl(2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-l-yl)-4-fluoro-3-hydroxy-4- methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanate.
A compound produced by the present process, or pharmaceutically acceptable salt or ester or solvate of said compound, can be used to preparing pharmaceutical compositions by combining the compound, or salt or ester or solvate thereof, with one or more pharmaceutical acceptable excipients, diluents or carriers.
For use in medicine, the salts of the compounds of this invention refer to non-toxic "pharmaceutically acceptable salts." FDA approved pharmaceutical acceptable salt forms (Ref. International J. Pharm. 1986, 33, 201-217; J. Pharm. Sci., 1977, Jan, 66 (1)) include pharmaceutically acceptable acidic/anionic or basic/cationic salts.
Pharmaceutically acceptable acidic/anionic salts include, and are not limited to acetate, benzenesulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate, diphospate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, tannate, tartrate, teoclate, tosylate and triethiodide. Pharmaceutically acceptable basic/cationic salts include, and are not limited to aluminum, benzathine, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, procaine, sodium and zinc.
Pharmaceutically acceptable ester derivatives in which one or more free hydroxy groups are esterified in the form of a pharmaceutically acceptable ester are particularly prodrug esters that may be convertible by solvolysis under physiological conditions to the compounds of the present invention having free hydroxy groups.
Pharmaceutical compositions incorporating compounds produced by the present process, or salts, esters or solvates thereof, may be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. These pharmaceutical compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee- making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen. The compound having formula I or a pharmaceutical composition comprising a compound having formula I according to the present invention can be administered to a patient, which may be homo sapiens or animal, by any suitable means. Such medicaments can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
For oral administration, the pharmaceutical compositions will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while cornstarch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
The compounds of the invention may also be presented as liposome formulations.
In general a suitable dose will be in the range of 0.1 to 300 mg per kilogram body weight of the recipient per day. A preferred lower dose is 0.5 mg per kilogrm body weight of recpient per day, a more preferred lower dose is 1 mg per kilogram body weight of recipient per day. A suitable dose is preferably in the range of 1 to 50 mg per kilogram body weight per day, and more preferably in the range of 1 to 10 mg per kilogram body weight per day. The desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.
The present invention will now be described by way of example only with reference to the following examples and the following figures, wherein:
Fig. 1 shows the HPLC spectrum of the product of Example 1;
Fig. 2 shows the HPLC spectrum of the product of Example 42;
Fig. 3 shows the reaction scheme and HPLC spectrum of the product of Example 43; Fig. 4 shows the reaction scheme and HPLC spectrum of the product of Example 44; Fig. 5 shows the reaction scheme and HPLC spectrum of the product of Example 45; Fig. 6 shows the reaction scheme and HPLC spectrum of the product of Example 46; Fig. 7 shows the HPLC spectrum of the product of Example 47; and
Fig. 8 shows the HPLC spectrum of the product of Example 48.
The following example sets out the experimental procedure that was employed in each of the Examples for which data are set out below.
Experimental Procedure
Example:
Figure imgf000024_0001
A dry round bottomed flask is charged with a magnetic stirring bar, 2'-C methyl-6-O- methylguanosine (2'CMe60MeG) (106.0 mg, 0.34 mmol.) and catalytic amount of copper (II) trifluoromethane sulfonate (12.32 mg, 0.34 mmol, 0.1 equiv.). The flask is sealed with a rubber septum and purged with dry argon. Anhydrous 1,2-dimethoxyethane (DME, 10 mL) is added via syringe and the resulting light blue solution is stirred at room temperature for 5-10 minutes. In a separate vial, a solution of naphthyl (Oneopentyl-L-alaninyl) phosphorochloridate (131 mg, 0.34 mmol., 1 equiv.) in 2-3 mL of anhydrous THF is prepared. To the nucleoside solution is then added N,N-diisopropylethylamine (DIPEA)(62.3 mg, 0.48 mmol., 84.0 μί, 1.5 equiv.) followed by the dropwise addition of the phosphorochloridate solution previously prepared. Upon addition of the base, the solution turned from light blue to dark green and a white precipitate appeared. Addition of the phosphorochloridate solution causes the disappearance of the precipitate and the color of the solution to turn to dark blue. The mixture is then stirred at room temperature for 12 hours. The reaction is monitored by HPLC, according to the following protocol:
a 0.1-0.2 mL aliquot of solution is withdraw from the flask, under argon, via syringe and diluted with HPLC grade methanol, filtered and further diluted with a mixture of acetonitrile/ water 10:90. The resulting solution is then injected into HPLC and analyzed (Reverse-phase C-18 column, eluting with H20/MeCN from 90/10 to 0/100 in 30 min, Flow = 1 mL/min, λ = 254 ran and λ = 280 nm). A 38% yield and 1 :8 Sp to Rp diastereomeric ratio are estimated by integration of the product and starting material peaks. When the reaction is completed, the solvent is evaporated under reduced pressure, and the residue is purified by column chromatography on silica gel with gradient elution DCM: MeOH 98:2 to 94:6. The residue from the column is taken up in dichloromethane and washed with 0.5 M HC1 (3 x 10 mL). The organic layer is separated, dried over sodium sulfate, filtered and evaporated to give the title compound as white solid (isolated yield: 40 mg, 20%). The isomer ratio obtained was 1 :5 in favor of the Rp isomer as judged from the HPLC of the pure compound, as shown in Fig. 1.
The procedure outlined above was followed in the following examples.
Examples 1 to 5
The above procedure was followed employing 2'CMe60MeG, as set out above, as the nucleoside and each of the phosphorochlcridates whose structures are set out immediately below, arranged in order of Example 1 to Example 5, and the following experimental conditions: Nucleoside. 100 mg, phosphorochloridate 1 equiv., Cu(OTf)2 0.1 equiv., DIPEA 1.5 equiv., DME 10 mL, room temperature, 12-18 hours. Example 5 is a reference example.
Figure imgf000026_0001
The results of the preparative processes in terms of the Rp:Sp ratio of enantiomers isolated and the HPLC yield achieved are given in Table 1 below. "2'CMeG" in Table 1 stands for "2'CMe60MeG", as set out above.
Figure imgf000026_0002
Table 1. Variation of the phosphorochloridate
Examples 6 to 12
Following the experimental procedure set out above, one equivalent of naphthyl (Oneopentyl-L-alaninyl)phosphorochloridate was reacted with a range of nucleosides under the following conditions: Nucleoside 100 mg, phosphorochloridate 1 equiv., Cu(OTf)2 0.1 equiv., DIPEA 1.5 equiv., DME 10 mL, Room Temperature, 12-18 hours. Example 8 is a reference example.
The structure of naphthyl(Oneopentyl-L-alaninyl)phosphorochloridate and the structures of the nucleosides arranged in order of Example 6 to Example 12, are given below:
Figure imgf000027_0001
The results in terms of the ratio of Rp:Sp and yield achieved are given in Table 2 below.
Example Nucleoside Phosphorochloridate Ratio Yield
6 2'CMeG L-Ala neopentyl, naphthyl 1:8 38%
7 2',3'iPr A L-Ala neopentyl, naphthyl 1:1.1 12%
8 Abacavir L-Ala neopentyl, naphthyl - -
9 Gemcitabine L-Ala neopentyl, naphthyl 1:1 Trace
10 Boc L-Ala neopentyl, naphthyl 1:2.2 5%
Gemcitabine 11 FUDR L-Ala neopentyl, naphthyl 1 :2.5 30%
12 d4t L- Ala neopentyl, naphthyl 1:1.8 50%
Table 2. Nucleoside variation
Examples 13 to 14 Copper catalyst
Following the experimental procedure set out above and the following experimental conditions: Nucleoside 100 mg, phosphorochloridate 1 equiv., CU(X)Y 0.1 equiv., NEt3 1.5 equiv., THF 20 mL, Room Temperature, 12-18 hours, other copper salts in place of Cu(OTf>2 were tested as the catalyst. The copper salts employed and the results in terms of the ratio Rp:Sp of enantiomers and the yield achieved are given in the Table 3 below.
Figure imgf000028_0001
Table 3. Screening of copper salts Examples 15 to 18
Using the experimental procedure set out above, 2'CMe60MeG as the nucleoside, naphthyl(oneopentyl-L-alaninyl)phosphorochloridate as the phosphorochloridate and the following experimental conditions: Nucleoside 100 mg, phosphorochloridate 1 equiv., Me(OTf)Y 0.1 equiv., NEt3 1.5 equiv., THF 20 mL, room temperature, N2 atmosphere, 12- 18 hours, metal triflates other than copper triflate were screened. The reaction is set out below. Example 15 is a reference example.
Figure imgf000029_0001
The results in terms of the ratio Rp:Sp of enantiomers achieved and the yield achieved are set out in Table 4 below.
Figure imgf000029_0002
Table 4. Screening of other metal triflates; * the isomers ratio of Rp:Sp was slightly reversed (results of two runs).
In addition, TiCl4 as well as B(C6F5) were also tested as catalyst. With titanium tetrachloride no diastereoselectivity was observed (1 :1 ratio between the two isomers in 11 % yield), meanwhile with tris(pentaflucrophenyl)boron no reaction was observed.
Examples 19 to 22
Using the experimental procedure set out above, 2'CMe60MeG as the nucleoside, naphthyl (oneopentyl-L-alaninyl) phosphorochloridate as the phosphorochloridate and the following experimental conditions Nucleoside: 100 mg, 1 equivalent; Cu(OTf)2 0.1 equivalents; phosphorochloridate 1 equivalent; base 1.5 equivalents; THF 20 mL, Room Temperature, 12 hours, different bases were screened. The bases used and the results achieved in terms of Rp:Sp ratio of enantiomers and yield achieved are set out in Table 5 below. Example 22 uses DMAP, which is 4-dimethylaminop>Timidine, as the base, and is a reference example.
Example Cu(OTf)2 Base
Ratio (yield) (Equiv.) (1.5 equiv.)
Figure imgf000030_0001
Table 5. Variation of base
Examples 23 to 28 Solvent Screening
Following the experimental procedure above and using 2'CMe60MeG as the nucleoside and naphthyl(onepentyl-L-alaninyl)phosphorochloridate as the phosphorochloridate and the following experimental conditions: Nucleoside: 100 mg, 1 equivalent; Cu(OTf 2 0.1 equivalents; Phosphorochloridate 1 equivalent; NEt3 1.5 equivalents; solvent 20 mL, Room Temperature, 12 hours, varying solvent media for use in step (i) to dissolve the nucleoside compound and the metal salt catalyst were investigated. The results in terms of the ratio Rp:Sp of enantiomers and the yield achieved are set out in Table 6 below. Examples 24, 25, 27 and 28 are reference examples. "DCM" stands for dichloromethane (CH2CI2).
Figure imgf000030_0002
Table 6 Solvent screening
Examples 29 to 35 Using the experimental procedure set out above, gemcitabine (100 mg) was employed as the nucleoside and naphthyl(isopropyl-L-alaninyl)phosphorochoridate (1 molar equiv) was employed as the phosphorochloridate. For each example, the catalyst (MX), base and solvent were employed, as set out in the reaction scheme and in Table 7 below. Example 29 employed 10 ml THF and 2 ml MeCN. Table 7 gives, for each example, the total yield and the ratio of Rp:Sp enantiomers achieved. Example 31, employing Ti(OiPr)4 as the catalyst, is a reference example. In Table 7, AA indicates the amino acid moiety corresponding to - CNHCR^COz-
Figure imgf000031_0001
Figure imgf000031_0002
Table 7 Gemcitabine as the nucleoside
Examples 36 to 42 Using the experimental procedure set out above, 2'deoxy-2'fluorouridine (100 mg) was employed as the nucleoside and naphthyl(iso-propyl-L-alaninyl)phosphorochloridate (1 molar equiv) was employed as the phosphorochloridate. The catalyst, base and solvent for each example are set out in Table 8 below. In each case, the reaction took place at room temperature under nitrogen and for 24 hours. Examples 38 and 41 are reference examples.
Figure imgf000032_0001
Table 8 2'deoxy-2' fluorouridine as the nucleoside
The HPLC spectrum for the product of Example 42 is shown in Fig. 2.
Example 43
Using the experimental procedure set out above, nelarabine was employed as the nucleoside (lOOmg) and naphthyl(oneopentyl-L-alaninyl)phosphorochloridate (1 molar equiv) was employed as the phosphorochloridate. Cu(OTf)2 (0.1 equiv) was employed as the catalyst. NEt3 (1.5 equiv) was employed as the base and 10ml of THF were employed as the solvent. The reaction took place at room temperature under argon for 12 hours.
The phosphoramidated nelarabine reaction product was produced in a yield of 80% and comprised a ratio of Rp:Sp enantiomers of 3.6: 1.
The reaction scheme for the diastereoselective synthesis of protide via metal catalysis with respect to nelarabine of the present example and the HPLC of the reaction product are set out in Fig. 3. A/B in Fig. 3 refers to Rp/Sp.
Example 44
Using the above experimental procedure, clofarabine (100 mg) was employed as the nucleoside and naphthyl(oneopentyl-L-alaninyl)phosphorochloridate (1 molar equiv) was employed as the phosphorochloridate. Cu(OTf)2 (0.1 equiv) was employed as the catalyst. NEt3 (1.5 equiv) was employed as the base and 10 ml of THF were employed as the solvent. The reaction took place at room temperature under argon for 12 hours. The phosphoramidated clofarabine reaction product was achieved in a yield of about 40% and comprised a ratio of Rp:Sp enantiomers of 1 : 1.5.
The reaction scheme for the diastereoselective synthesis of protide via metal catalysis with respect to clofarabine of the present example and the HPLC spectrum of the reaction product are set out in Fig. 4. A/B in Fig. refers to Rp/Sp.
Example 45 Using the experimental procedure set out above, 2'deoxy-2'fluorouridine (100 mg) was employed as the nucleoside and naphthyl(iso-propyl-L-alaninyl)phosphochloridate (1 molar equiv.) was employed as the phosphorochloridate. 0.2 molar equivalents of Cu(OC(0)CF3)2 were used as the catalyst. 1.5 molar equivalents of NEt3 were employed as the base. 10 ml of DME were employed as the solvent. The reaction took place at room temperature under nitrogen for 12 hours.
The phosphoramidated 2'deoxy-2'fluoruridine reaction product was produced in a yield of 35% and comprised a ratio of Rp:Sp enantiomers of 1 :5.3.
The reaction scheme of the present example and the HPLC spectrum of the reaction product are set out in Fig. 5. Example 46
Using the experimental procedure set out above, Boc gemcitabine (100 mg) was employed as the nucleoside and naphthyl(iso-propyl-L-alaninyl)phosphorochloridate (1 molar equiv.) was employed as phosphorochloridate. 0.2 molar equivalents of Cu(OC)(0)CF3)2 were used as the catalyst. NEt3 (1.5 equiv) were employed as the base. 50 ml DME were employed as the solvent. The reaction took place under nitrogen at room temperature for 24 hours.
The phosphoramidated gemcitabine reaction product was produced in a yield of 9% and comprised a ratio of Rp:Sp enantiomers of 1 :9.
The reaction scheme of the present example and the HPLC spectrum of the reaction product are set out in Fig. 6.
Figure imgf000034_0001
Example 47 Using the experimental procedure set out above, 4-amino-l-((2R,3R,4R5R)-3-fluoro-4- hydroxy-5-(hydroxymemyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(l H)-one (100 mg) was employed as the nucleoside and 2 molar equivalents of phenyl(isopropyl-L- alaninyl)phosphorochloridate (150 mg) were employed as the phosphorochloridate. 0.5 molar equivalents of Cu(CF3C02)2 (30 mg) were employed as the catalyst. 1.5 molar equivalents of DIPEA (55 microlitres) were employed as the base and 10 ml of DME were employed as the solvent. The reaction took place at room temperature for 24 hours.
The reaction scheme of the present example is set out below.
Figure imgf000035_0001
The phosphoramidated reaction product was produced in a yield of 20% and comprised ratio of Rp:Sp enantiomers of 1 :66.
The HPLC of the phosphoramidated reaction product is set out in Fig. 7.
Example 48
Using the experimental procedure set out above, 3'-boc gemcitabine (lOOmg) was employed as the nucleoside and 2 molar equivalents of phenyl(benzyl-L- alaninyl)phosphoramidate (150 mg) were employed as the phosphorchloridate. 0.5 molar equivalents of tris(acetylacetonato)FeIII (56 mg) were employed as the catalyst. 1.5 molar equivalents DIPEA (55 microlitres) were employed as the base and 10 ml of THF were employed as the solvent. The reaction took place at room temperature under nitrogen for 24 hours. The reaction scheme of the present example is set out below.
Figure imgf000036_0001
The phosphoramidated reaction product was produced in yield of 45% and comprised ratio of Rp:Sp enantiomers of 3:1.
The HPLC of the phosphoramidated reaction product is set out in Fig. 8.

Claims

1. A process for the preparation of a compound of Formula I, wherein Formula I is:
Figure imgf000037_0001
wherein:
Ar is selected from C6-30aryl and C6-3oheteroaryl, each of which is optionally substituted;
Ri, R2 and R3 are, independently, selected from H and the group consisting of C1-20alkyl, C2-20alkenyl, C1-20alkoxy,
Figure imgf000037_0002
C2- 0alkynyl, C3-2- cycloalkylC6-30aryl, C6-30aryloxy and Cs^oheterocyclyl, any of which is optionally substituted;
Ti and T2 are linked together and together are selected from the group consisting of:
Figure imgf000037_0003
where T3 is selected from the group consisting of H and -COOC1-6alkyl and T4 and T5 are, independently, selected from the group consisting of H, F, CI, Br, I, OH and methyl (CH3); and B is selected from the group consisiing of a heterocyclic moiety derived from purine and a heterocyclic moiety derived from pyrimidine; comprising the steps of:
(i) dissolving a compound of Formula II in a solvent selected from the group consisting of an ethereal solvent, acetonitrile and mixtures thereof and admixing the dissolved compound of Formula II with a base, wherein Formula II is:
Figure imgf000038_0001
where Tl5 T2 and B have the same meanings set out with respect to Formula I;
(ii) admixing the product of step (i) with a compound of Formula III, wherein Formula III is:
Figure imgf000038_0002
where Ar, R1? R2 and R3 have the same meanings set out with respect to Formula I, wherein step (ii) takes place in the presence of a catalyst comprising a metal salt wherein the metal salt is selected from the group consisting of metal salts of Cu, Fe, La and Yb.
2. The process of claim 1 wherein the catalyst is admixed with the nucleoside compound of Formula II, prior to the dissolution of the compound of Formula II in the solvent of step (i).
3. The process of claim 1 or claim 2 wherein the catalyst is a copper salt.
4. The process of claim 3 wherein the catalyst is selected from the group consisting of Cu(OTf)2, CuCl, CuBr, Cul, Cu(OAc)2 and CuS04, and preferably, is Cu(OTf)2.
5. The process of claim 3 wherein the catalyst is selected from the group consisting of Cu(OAc)2 and Cu(OC(0)CF3)2.
6. The process of claim 1 or claim 2 wherein the catalyst is a metal salt with a metal in an oxidation state of more than 1.
7. The process of claim 6 wherein the metal salt is an OTf salt.
8. The process of claim 7 wherein the metal salt is selected from the group consisting of Cu(OTf)2, Yb(OTf 3, Fe(OTf)3 and La(OTf)3 and, preferably, is Cu(OTf)2.
9. The process of any one of claims 1 to 3 wherein the catalyst comprises a metal salt in which a metal component is in the form of a complex where a metal cation component is co-ordinated with one or more ligands.
10. The process of claim 9 wherein the metal salt is selected from the group consisting of Cu(MeCN)4 CF3S03 and Cu(OTf) C6H6.
11. The process of any one of claims 1 to 10 wherein B in the compounds of Formulae I and II is the purine derived moiety, where the N atom marked with * links directly to the CI atom of the sugar moiety:
Figure imgf000040_0001
where each of X and Z is, independently, selected from H, OH, F, CI, Br, I, OC1-6alkyl, Ci_ 6alkyl and NR7R8, where each of R7 and Rg is, independently, selected from H and Ct. 6alkyl; and
Y is selected from H, OH, OC1-6alkyl, SH, SC1-6alkyl, F, CI, Br, I, d_6alkyl, C2-8alkynyl and NR9R10 where each of R9 and Ri0 is, independently, selected from H and C1-6 alkyl.
12. The process of any one of claims I to 10 wherein B in the compounds of Formulae I and II is the pyrimidine derived moiety, where the N atom marked with * links directly with the CI atom of the sugar moiety:
Figure imgf000040_0002
where U is selected from the group consisting of H, C1-6alkyl, F, CI, Br and I; and n is 0 or 1,
wherein
when n is 0, V is -N¾ and a double bond exists between position 3 and position 4, and when n is 1, V is =0.
13. The process of any one of claims 1 to 12 wherein B comprises one or more members selected from the group consisting of: an NH moiety, where N is a heteroatom in an aromatic ring moiety of B, and one or more exocyclic heteroatoms selected from the group consisting of N, O, S and CI directly linked to an aromatic ring moiety of B.
14. The process of any one of claims 1 to 13 wherein the compounds of Formulae I and II have Ti and T2 comprising T3, T4 and T5.
15. The process of any one of claims 1 to 14 wherein the compounds of Formulae I and III have Ar as naphthyl or phenyl and, preferably, is naphthyl.
16. The process of any one of claims 1 to 15 wherein R\ is selected from the group consisting of a tertiary alkyl moiety and benzyl.
17. The process of any one of claims 1 to 16 wherein at least one of R2 and R3 is a secondary or tertiary alkyl moiety.
18. The process of any one of claims 1 to 17 wherein the ethereal solvent employed in step (i) is selected from the group consisting of 1,2-dimethoxyethane, tetrahydrofuran, 1,4- dioxane, diethyl ether, anisole, dimethoxybenzene and mixtures thereof.
19. The process of any one of claims 1 to 18 wherein the base employed in step (i) is selected from the group consisting of: NR4R5R6, where R4, R5 and R^ are selected, independently, from the group consisting of C1-3alkyl and H, provided that at least two of R4, R5 and Re are, independently, C1-3alkyl; and l,8-diazabicyclo[5.4.0]undec-7-ene.
20. The process of any one of claims 1 to 19 including further steps of removing the solvent and subjecting the residue to column chromatography.
21. The product of the process of any one of claims 1 to 20 wherein the product comprises a ratio of enantiomers of Rp to Sp that is not 1:1.
22. The product of claim 21 wherein the product comprises a ratio of Rp enantiomer to Sp enantiomer that is greater or less than 1, preferably greater or less than 2, more preferably greater or less than 5, even more preferably greater or less than 7.5.
23. A pharmaceutical composition comprising the product of any one of claims 1 to 22 together with pharmaceutical acceptable carrier, diluent or excipient.
The pharmaceutical composition of claim 23 for use in a method of treatment of or a viral infection, suitably in homo sapiens.
25. The pharmaceutical composition of claim 24 wherein the product is 2-amino-6- methoxy-9-(2 ' -C-methyl-P-D-ribofuranosyl)purine 5 ' -O- [a-naphthyl-(2,2- dimethylpropoxy-L-ananinyl)] phosphate for use in treating HCV.
26. The process of any one of claims 1, 2, 3 and, when dependent on claim 3, 11 to 20, wherein the metal salt is Cu(OAc).
27. The product of the process of claim 26 wherein the product comprises a ratio of enantiomers of Rp to Sp that is not 1:1.
28. The product of claim 27 wherein the product comprises a ratio of Rp enantiomer to Sp enantiomer that is greater or less than 1, preferably greater or less than 2, more preferably greater or less than 5, even more preferably greater or less than 7.5.
29. A pharmaceutical composition comprising the product of any one of claims 26 to 28 together with a pharmaceutical acceptable carrier, diluent or excipient.
30. The pharmaceutical composition of claim 29 for use in a method of treatment of cancer or viral infection, suitably in homo sapiens.
31. The pharmaceutical composition of claim 30 wherein the product is 2-amino-6- methoxy-9-(2'-C-methyl-P-D-ribofuranosyl)purine 5'-0-[a-naphthyl]-(2,2- dimethylpropoxy-L-ananinyl)] phosphate for use in treating HCV.
32. The process of any one of claims 1, 2, 6 and, when dependent on claim 6, 11 to 20, wherein the metal salt is selected from the group consisting of tris(acetylacetonato)iron(III) and bis(acetylacetonato)iron(II).
33. The product of the process of claim 32 wherein the product comprises a ratio of enantiomers of Rp to Sp that is not 1:1.
34. The product of claim 33 wherein the product comprises a ratio of Rp enantiomer to Sp enantiomer that is greater or less than 1, preferably greater or less than 2, more preferably greater or less than 5, even more preferably greater or less than 7.5.
35. A pharmaceutical composition comprising the product of any one of claims 32 to 34 together with a pharmaceutical acceptable carrier, diluent or excipient.
36. The pharmaceutical composition of claim 35 for use in a method of treatment of cancer or viral infection, suitably in homo sapiens.
37. The pharmaceutical composition of claim 36 wherein the product is 2-amino-6- methoxy-9-(2'-C-methyl-P-D-ribofuranosyl)purine 5'-0-[<x-naphthyl]-(2,2- dimethylpropoxy-L-ananinyl)] phosphate for use in treating HCV.
PCT/GB2013/053018 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs WO2014076490A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SG11201503750YA SG11201503750YA (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
MX2015006195A MX2015006195A (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs.
JP2015542357A JP2016506371A (en) 2012-11-16 2013-11-15 Methods for preparing nucleoside prodrugs
EA201590955A EA028871B1 (en) 2012-11-16 2013-11-15 Process for preparing chemical compounds
AU2013346515A AU2013346515B2 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
EP13792965.9A EP2920192B1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
CN201380069952.2A CN104903339A (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
BR112015011155-6A BR112015011155B1 (en) 2012-11-16 2013-11-15 PHARMACEUTICAL COMPOSITION COMPRISING A RP/SP MIXTURE GEMCITABIN-[PHENYL-BENZYLOXY-1-ALANINYL)]-PHOSPHATE
PL17169878T PL3235824T3 (en) 2012-11-16 2013-11-15 Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
US14/442,987 US10005810B2 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
KR1020157015861A KR20150103669A (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
EP17169878.0A EP3235824B1 (en) 2012-11-16 2013-11-15 Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
ES13792965.9T ES2618732T3 (en) 2012-11-16 2013-11-15 Procedure for preparing nucleoside prodrugs
CA2891266A CA2891266C (en) 2012-11-16 2013-11-15 Gemcitabine phosphate mixture for the treatment of cancer
NZ708177A NZ708177A (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
IN4090DEN2015 IN2015DN04090A (en) 2012-11-16 2013-11-15
IL238792A IL238792A (en) 2012-11-16 2015-05-13 Process for preparing nucleoside prodrugs
PH12015501090A PH12015501090A1 (en) 2012-11-16 2015-05-15 Process for preparing nucleoside prodrugs
HK15111437.1A HK1210784A1 (en) 2012-11-16 2015-11-19 Process for preparing nucleoside prodrugs
US15/994,378 US11040997B2 (en) 2012-11-16 2018-05-31 Process for preparing nucleoside prodrugs
CY20191100503T CY1121663T1 (en) 2012-11-16 2019-05-09 GEMCITAVINE-[PHENYL-(BENZYLOXY-L-ALANINYL)]-PHOSPHATE RP/SP MIXTURE
US17/323,367 US20220033433A1 (en) 2012-11-16 2021-05-18 Process for preparing nucleoside prodrugs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB1220666.0 2012-11-16
GB1307314.3 2013-04-23
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/442,987 A-371-Of-International US10005810B2 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
US15/994,378 Continuation US11040997B2 (en) 2012-11-16 2018-05-31 Process for preparing nucleoside prodrugs

Publications (1)

Publication Number Publication Date
WO2014076490A1 true WO2014076490A1 (en) 2014-05-22

Family

ID=49622844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2013/053018 WO2014076490A1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Country Status (28)

Country Link
US (3) US10005810B2 (en)
EP (3) EP3150616B1 (en)
JP (5) JP2016506371A (en)
KR (1) KR20150103669A (en)
CN (2) CN104903339A (en)
AU (1) AU2013346515B2 (en)
CA (1) CA2891266C (en)
CL (1) CL2015001307A1 (en)
CY (2) CY1119161T1 (en)
DK (2) DK3150616T3 (en)
EA (1) EA028871B1 (en)
ES (3) ES2627195T3 (en)
HK (1) HK1210784A1 (en)
HR (2) HRP20170791T1 (en)
HU (2) HUE044605T2 (en)
IL (1) IL238792A (en)
IN (1) IN2015DN04090A (en)
LT (2) LT3150616T (en)
MX (1) MX2015006195A (en)
MY (1) MY176133A (en)
NZ (1) NZ708177A (en)
PH (1) PH12015501090A1 (en)
PL (2) PL3235824T3 (en)
PT (2) PT3235824T (en)
RS (2) RS56038B1 (en)
SG (3) SG11201503750YA (en)
SI (2) SI3235824T1 (en)
WO (1) WO2014076490A1 (en)

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105153257A (en) * 2014-06-12 2015-12-16 正大天晴药业集团股份有限公司 Preparation method of sofosbuvir
WO2015081133A3 (en) * 2013-11-27 2015-12-17 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
WO2015198058A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
CN105254694A (en) * 2014-07-14 2016-01-20 正大天晴药业集团股份有限公司 Deuterated nucleoside derivative
CN105461773A (en) * 2014-09-30 2016-04-06 江苏豪森药业集团有限公司 Preparation method and intermediate of sofosbuvir
CN105461774A (en) * 2014-09-30 2016-04-06 江苏豪森药业集团有限公司 Preparation method of sofosbuvir
WO2016055769A1 (en) * 2014-10-06 2016-04-14 Nucana Biomed Limited Methods of separating gemcitabine-phosphate diastereoisomers
CN106397515A (en) * 2015-07-28 2017-02-15 广东东阳光药业有限公司 An improved sofosbuvir preparation method
WO2017045582A1 (en) * 2015-09-16 2017-03-23 博瑞生物医药（苏州）股份有限公司 Preparation method of nucleoside phosphoramidate prodrugs and intermediates thereof
WO2017045583A1 (en) * 2015-09-16 2017-03-23 博瑞生物医药（苏州）股份有限公司 Composition rich in single isomer nuc-1031 and preparation method and use thereof
CN106661074A (en) * 2014-07-31 2017-05-10 桑多斯股份公司 Synthesis of phosphoramidates
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
WO2017098252A1 (en) * 2015-12-11 2017-06-15 Nucana Biomed Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
WO2017109485A1 (en) * 2015-12-23 2017-06-29 Nucana Biomed Limited Crystalline form of gemcitabine
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
WO2017207989A1 (en) * 2016-06-01 2017-12-07 Nucana Biomed Limited Adenosine derivatives for use in the treatment of cancer
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018015821A1 (en) * 2016-07-20 2018-01-25 Optimus Drugs (P) Limited An improved process for the preparation of sofosbuvir
WO2018019188A1 (en) * 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 Polymorph of nucleoside phosphoramidate prodrug and preparation method therefor
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
CN108135920A (en) * 2015-10-05 2018-06-08 努卡那有限公司 Combination treatment
WO2018113652A1 (en) * 2016-12-23 2018-06-28 四川科伦博泰生物医药股份有限公司 Nucleoside phosphate compound and preparation method and use thereof
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US10117888B2 (en) 2014-06-25 2018-11-06 NuCana plc Formulation comprising a gemcitabine-prodrug
JP2018532718A (en) * 2015-09-16 2018-11-08 ブライトジーン バイオ−メディカル テクノロジー カンパニー リミテッド Phosphoramidate compound, production method thereof and crystal
WO2018229493A2 (en) 2017-06-14 2018-12-20 NuCana plc Synthesis of phosphate derivatives
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
RU2731385C1 (en) * 2016-10-07 2020-09-02 ООО "Вириом" Macroheterocyclic nucleoside derivatives and analogues thereof, production and use
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11040997B2 (en) 2012-11-16 2021-06-22 NuCana plc Process for preparing nucleoside prodrugs
US11186599B2 (en) 2018-06-12 2021-11-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof
US11690860B2 (en) 2018-04-10 2023-07-04 Atea Pharmaceuticals, Inc. Treatment of HCV infected patients with cirrhosis

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
WO2017090264A1 (en) * 2015-11-27 2017-06-01 大原薬品工業株式会社 5'-position dibenzyl phosphoric acid ester of 5-azacytidine or 2'-deoxy body thereof
KR102592899B1 (en) 2017-02-01 2023-10-24 아테아 파마슈티컬즈, 인크. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
RU2740058C1 (en) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Method of producing sofosbuvir and phosphoramidates
CN112409431B (en) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 Cytarabine structural analogue, and preparation method and application thereof
CN113549076B (en) * 2021-07-23 2022-12-06 中国药科大学 Polysubstituted purine compound and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123672A1 (en) * 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
EP1167972B1 (en) 1998-01-23 2017-03-08 Kiadis Pharma Intellectual Property B.V. Enzyme catalyzed therapeutic agents
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO2003068162A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
WO2004041203A2 (en) 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2007020193A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (en) * 2008-12-08 2010-07-27 Medivir Ab URACIL CYCLOPROPYLL NUCLEOTIDES
BRPI1004575A2 (en) * 2009-01-09 2016-04-05 Inhibitex Inc compound, pharmaceutical composition, method of treating viral infections, phosphorus diastereomers separation method
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
JP5937073B2 (en) * 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド Process for the preparation of diastereomeric pure phosphoramidate prodrugs
KR20130110170A (en) * 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. Substituted nucleotide analogs
EP2655392B1 (en) * 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
HUE060127T2 (en) * 2011-03-01 2023-02-28 NuCana plc Pharmaceutical formulation comprising a phosphoramidate derivative of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
KR20190060879A (en) * 2011-03-02 2019-06-03 제롬 쉔타그 Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
CA2852064A1 (en) * 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
SG11201503750YA (en) 2012-11-16 2015-06-29 Univ Cardiff Process for preparing nucleoside prodrugs
TW201542578A (en) * 2013-06-26 2015-11-16 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
SI3043803T1 (en) 2013-09-11 2022-09-30 Emory University Nucleotide and nucleoside compositions and their uses
EP3055319A4 (en) * 2013-10-11 2018-01-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015080949A1 (en) * 2013-11-27 2015-06-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Piperidine and piperazine derivatives and their use in treating viral infections and cancer
KR20160099090A (en) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 Nucleotides for the treatment of liver cancer
PL3119794T3 (en) 2014-06-25 2018-04-30 NuCana plc Formulation comprising a gemcitabine-prodrug
HRP20230584T1 (en) 2014-06-25 2023-09-15 NuCana plc Gemcitabine prodrugs
WO2016012781A1 (en) 2014-07-22 2016-01-28 Nucana Biomed Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3415149A1 (en) 2015-05-14 2018-12-19 NuCana plc Cancer treatments
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
EP3386998B1 (en) 2015-12-11 2021-11-10 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
KR102566461B1 (en) 2015-12-23 2023-08-14 뉴카나 피엘씨 combination therapy
EA037459B1 (en) 2015-12-23 2021-03-30 НУКАНА ПиЭлСи Combination therapy
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123672A1 (en) * 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JONG HYUN CHO ET AL: "Efficient Synthesis of Exo- N -carbamoyl Nucleosides: Application to the Synthesis of Phosphoramidate Prodrugs", ORGANIC LETTERS, vol. 14, no. 10, 18 May 2012 (2012-05-18), pages 2488 - 2491, XP055092853, ISSN: 1523-7060, DOI: 10.1021/ol300777p *
JONG HYUN CHO ET AL: "Efficient synthesis of nucleoside aryloxy phosphoramidate prodrugs utilizing benzyloxycarbonyl protection", TETRAHEDRON, vol. 67, no. 30, 1 July 2011 (2011-07-01), pages 5487 - 5493, XP055092851, ISSN: 0040-4020, DOI: 10.1016/j.tet.2011.05.046 *

Cited By (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040997B2 (en) 2012-11-16 2021-06-22 NuCana plc Process for preparing nucleoside prodrugs
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2015081133A3 (en) * 2013-11-27 2015-12-17 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
WO2015188782A1 (en) * 2014-06-12 2015-12-17 正大天晴药业集团股份有限公司 Method for preparing sofosbuvir
CN105153257A (en) * 2014-06-12 2015-12-16 正大天晴药业集团股份有限公司 Preparation method of sofosbuvir
KR102407935B1 (en) * 2014-06-25 2022-06-10 뉴카나 피엘씨 Gemcitabine prodrugs
US11707477B2 (en) 2014-06-25 2023-07-25 NuCana plc Formulation comprising a gemcitabine-prodrug
AU2015278899B2 (en) * 2014-06-25 2019-07-18 NuCana plc Gemcitabine prodrugs
CN106459129A (en) * 2014-06-25 2017-02-22 努卡那生物医药有限责任公司 Gemcitabine prodrugs
US11040051B2 (en) 2014-06-25 2021-06-22 NuCana plc Formulation comprising a gemcitabine-prodrug
EA034890B1 (en) * 2014-06-25 2020-04-02 НУКАНА ПиЭлСи Gemcitabine prodrugs
KR20170043479A (en) * 2014-06-25 2017-04-21 뉴카나 바이오메드 리미티드 Gemcitabine prodrugs
US10662213B2 (en) 2014-06-25 2020-05-26 NuCana plc Gemcitabine prodrugs
CN111214480A (en) * 2014-06-25 2020-06-02 努卡那有限公司 Gemcitabine prodrugs
TWI695718B (en) * 2014-06-25 2020-06-11 英商努卡那公眾有限公司 Prodrug
TWI758728B (en) * 2014-06-25 2022-03-21 英商努卡那公眾有限公司 Prodrug
JP2017519014A (en) * 2014-06-25 2017-07-13 ヌカナ バイオメド リミテッド Gemcitabine prodrug
US10117888B2 (en) 2014-06-25 2018-11-06 NuCana plc Formulation comprising a gemcitabine-prodrug
JP2020152725A (en) * 2014-06-25 2020-09-24 ヌカナ ピーエルシー Gemcitabine prodrugs
US10786523B2 (en) 2014-06-25 2020-09-29 NuCana plc Formulation comprising a gemcitabine-prodrug
WO2015198058A1 (en) * 2014-06-25 2015-12-30 Nucana Biomed Limited Gemcitabine prodrugs
US11629164B2 (en) 2014-06-25 2023-04-18 NuCana plc Gemcitabine prodrugs
EP3757112A1 (en) * 2014-06-25 2020-12-30 Nucana PLC Gemcitabine prodrugs
KR20220080220A (en) * 2014-06-25 2022-06-14 뉴카나 피엘씨 Gemcitabine prodrugs
KR102563040B1 (en) * 2014-06-25 2023-08-02 뉴카나 피엘씨 Gemcitabine prodrugs
CN105254694A (en) * 2014-07-14 2016-01-20 正大天晴药业集团股份有限公司 Deuterated nucleoside derivative
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
CN106661074A (en) * 2014-07-31 2017-05-10 桑多斯股份公司 Synthesis of phosphoramidates
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461774A (en) * 2014-09-30 2016-04-06 江苏豪森药业集团有限公司 Preparation method of sofosbuvir
CN105461773B (en) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 Preparation method and intermediate of sofosbuvir
CN105461774B (en) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 Preparation method of sofosbuvir
CN105461773A (en) * 2014-09-30 2016-04-06 江苏豪森药业集团有限公司 Preparation method and intermediate of sofosbuvir
US10669300B2 (en) 2014-10-06 2020-06-02 NuCana plc Methods of separating gemcitabine-phosphate diastereoisomers
JP2017530172A (en) * 2014-10-06 2017-10-12 ヌカナ バイオメド リミテッド Method for separating gemcitabine phosphate diastereoisomers
KR20170090413A (en) * 2014-10-06 2017-08-07 뉴카나 바이오메드 리미티드 Methods of separating gemcitabine-phosphate diastereoisomers
JP2020128392A (en) * 2014-10-06 2020-08-27 ヌカナ ピーエルシー Methods of separating gemcitabine-phosphate diastereoisomers
CN112552362A (en) * 2014-10-06 2021-03-26 努卡那有限公司 Method for separating gemcitabine phosphate diastereoisomer
EA033118B1 (en) * 2014-10-06 2019-08-30 НУКАНА ПиЭлСи Methods of separating gemcitabine-phosphate diastereoisomers
EP3725794A1 (en) * 2014-10-06 2020-10-21 NuCana plc Crystalline form of gemcitabine-(s)-phosphate diastereoisomer
KR102532498B1 (en) 2014-10-06 2023-05-12 뉴카나 피엘씨 Methods of separating gemcitabine-phosphate diastereoisomers
WO2016055769A1 (en) * 2014-10-06 2016-04-14 Nucana Biomed Limited Methods of separating gemcitabine-phosphate diastereoisomers
AU2015329767B2 (en) * 2014-10-06 2020-03-12 NuCana plc Methods of separating gemcitabine-phosphate diastereoisomers
AU2020203714B2 (en) * 2014-10-06 2021-07-22 NuCana plc Methods of separating gemcitabine-phosphate diastereoisomers
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN107427530B (en) * 2015-03-06 2020-09-08 阿堤亚制药公司 β -D-2' -deoxy-2 ' α -fluoro-2 ' - β -C-substituted-2-modified-N for HCV treatment6-substituted purine nucleotides
US10005811B2 (en) 2015-03-06 2018-06-26 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10239911B2 (en) 2015-03-06 2019-03-26 Atea Pharmaceuticals, Inc. Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
CN107427530A (en) * 2015-03-06 2017-12-01 阿堤亚制药公司 2 N being modified that the β C of 2 ' deoxidations of β D, 2 ' α fluorine 2 ' for HCV therapy substitute6Substituted purine nucleotides
US10875885B2 (en) 2015-03-06 2020-12-29 Atea Pharmaceuticals, Inc. β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatment
US10870672B2 (en) 2015-03-06 2020-12-22 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10870673B2 (en) 2015-03-06 2020-12-22 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10000523B2 (en) 2015-03-06 2018-06-19 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10815266B2 (en) 2015-03-06 2020-10-27 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515A (en) * 2015-07-28 2017-02-15 广东东阳光药业有限公司 An improved sofosbuvir preparation method
CN106397515B (en) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 Improved preparation method of Sofosbuvir
JP2018532718A (en) * 2015-09-16 2018-11-08 ブライトジーン バイオ−メディカル テクノロジー カンパニー リミテッド Phosphoramidate compound, production method thereof and crystal
JP7280695B2 (en) 2015-09-16 2023-05-24 ブライトジーン バイオ－メディカル テクノロジー カンパニー リミテッド Composition rich in single isomer of NUC-1031, method for producing the same, and use thereof
US10538541B2 (en) 2015-09-16 2020-01-21 Brightgene Bio-Medical Technology Co., Ltd. Phosphoramidate compound and preparation method and crystal thereof
JP2018528957A (en) * 2015-09-16 2018-10-04 ブライトジーン バイオ−メディカル テクノロジー カンパニー リミテッド Method for producing nucleoside phosphoramidate type prodrug and its intermediate
JP2018528958A (en) * 2015-09-16 2018-10-04 ブライトジーン バイオ−メディカル テクノロジー カンパニー リミテッド Composition rich in single isomer of NUC-1031 and process for its production and use
WO2017045582A1 (en) * 2015-09-16 2017-03-23 博瑞生物医药（苏州）股份有限公司 Preparation method of nucleoside phosphoramidate prodrugs and intermediates thereof
WO2017045583A1 (en) * 2015-09-16 2017-03-23 博瑞生物医药（苏州）股份有限公司 Composition rich in single isomer nuc-1031 and preparation method and use thereof
AU2016322375B2 (en) * 2015-09-16 2020-07-09 Brightgene Bio-Medical Technology Co., Ltd. Composition rich in single isomer NUC-1031 and preparation method and use thereof
EP3351550A4 (en) * 2015-09-16 2019-05-15 BrightGene Bio-Medical Technology Co., Ltd. Phosphoramidate compound and preparation method and crystal thereof
US10689413B2 (en) 2015-09-16 2020-06-23 Brightgene Bio-Medical Technology Co., Ltd. Composition enriched in single isomer of NUC-1031 and preparation method and use thereof
US10913756B2 (en) 2015-09-16 2021-02-09 Brightgene Bio-Medical Technology Co., Ltd. Phosphoramidate compound and preparation method and crystal thereof
JP2018529740A (en) * 2015-10-05 2018-10-11 ニューカナ パブリック リミテッド カンパニー Combination therapy
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
CN108135920A (en) * 2015-10-05 2018-06-08 努卡那有限公司 Combination treatment
JP2019500420A (en) * 2015-12-11 2019-01-10 ニューカナ パブリック リミテッド カンパニー Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug NUC-1031
US11603382B2 (en) 2015-12-11 2023-03-14 NuCana plc Diastereoselective synthesis of phosphate derivatives
WO2017098252A1 (en) * 2015-12-11 2017-06-15 Nucana Biomed Limited Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
EA038658B1 (en) * 2015-12-11 2021-09-30 НУКАНА ПиЭлСи Process for preparation of gemcitabine prodrug nuc-1031 using diastereoselective enrichment of intermediate phosphate derivatives
EP4011896A1 (en) 2015-12-11 2022-06-15 NuCana plc Diastereoselective synthesis of (sp)-gemcitabine-[phenyl(benzoxy-l-alaninyl)]phosphate nuc-1031
US10774104B2 (en) 2015-12-11 2020-09-15 Laurus Labs Private Ltd Diastereoselective synthesis of phosphate derivatives
US11377467B2 (en) 2015-12-23 2022-07-05 NuCana plc Crystalline form of gemcitabine
WO2017109485A1 (en) * 2015-12-23 2017-06-29 Nucana Biomed Limited Crystalline form of gemcitabine
AU2016375860B2 (en) * 2015-12-23 2021-06-03 NuCana plc Crystalline form of gemcitabine
WO2017207989A1 (en) * 2016-06-01 2017-12-07 Nucana Biomed Limited Adenosine derivatives for use in the treatment of cancer
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018015821A1 (en) * 2016-07-20 2018-01-25 Optimus Drugs (P) Limited An improved process for the preparation of sofosbuvir
WO2018019188A1 (en) * 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 Polymorph of nucleoside phosphoramidate prodrug and preparation method therefor
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
US10946033B2 (en) 2016-09-07 2021-03-16 Atea Pharmaceuticals, Inc. 2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
RU2731385C1 (en) * 2016-10-07 2020-09-02 ООО "Вириом" Macroheterocyclic nucleoside derivatives and analogues thereof, production and use
US10899786B2 (en) 2016-12-23 2021-01-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
WO2018113652A1 (en) * 2016-12-23 2018-06-28 四川科伦博泰生物医药股份有限公司 Nucleoside phosphate compound and preparation method and use thereof
WO2018229493A2 (en) 2017-06-14 2018-12-20 NuCana plc Synthesis of phosphate derivatives
US11690860B2 (en) 2018-04-10 2023-07-04 Atea Pharmaceuticals, Inc. Treatment of HCV infected patients with cirrhosis
US11186599B2 (en) 2018-06-12 2021-11-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11707480B2 (en) 2020-02-27 2023-07-25 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11738038B2 (en) 2020-02-27 2023-08-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
US11813278B2 (en) 2020-02-27 2023-11-14 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Also Published As

Publication number Publication date
US20150291650A1 (en) 2015-10-15
RS58849B1 (en) 2019-07-31
DK3150616T3 (en) 2017-06-06
JP2019196360A (en) 2019-11-14
US11040997B2 (en) 2021-06-22
KR20150103669A (en) 2015-09-11
SG10201510322UA (en) 2016-01-28
US10005810B2 (en) 2018-06-26
PT3235824T (en) 2019-05-30
SI3150616T1 (en) 2017-08-31
CN104903339A (en) 2015-09-09
MX2015006195A (en) 2015-12-08
SG11201503750YA (en) 2015-06-29
HRP20190831T1 (en) 2019-08-23
IL238792A0 (en) 2015-06-30
PL3150616T3 (en) 2017-09-29
EP3150616A1 (en) 2017-04-05
PH12015501090B1 (en) 2015-07-27
CY1119161T1 (en) 2018-02-14
ES2725491T3 (en) 2019-09-24
JP2016506371A (en) 2016-03-03
HRP20170791T1 (en) 2017-08-25
HK1210784A1 (en) 2016-05-06
CY1121663T1 (en) 2020-07-31
EP3235824B1 (en) 2019-03-27
SI3235824T1 (en) 2019-08-30
LT3235824T (en) 2019-07-10
HUE033335T2 (en) 2017-11-28
US20220033433A1 (en) 2022-02-03
JP2023052536A (en) 2023-04-11
US20180273575A1 (en) 2018-09-27
CN111592577A (en) 2020-08-28
EA028871B1 (en) 2018-01-31
MY176133A (en) 2020-07-24
AU2013346515A1 (en) 2015-06-04
PH12015501090A1 (en) 2015-07-27
EP2920192A1 (en) 2015-09-23
SG10201510324YA (en) 2016-01-28
JP2018009000A (en) 2018-01-18
IN2015DN04090A (en) 2015-10-09
LT3150616T (en) 2017-07-25
PL3235824T3 (en) 2019-09-30
PT3150616T (en) 2017-06-09
EA201590955A1 (en) 2015-08-31
NZ708177A (en) 2017-08-25
ES2618732T3 (en) 2017-06-22
EP3235824A1 (en) 2017-10-25
HUE044605T2 (en) 2019-11-28
BR112015011155A2 (en) 2017-07-11
ES2627195T3 (en) 2017-07-27
CA2891266A1 (en) 2014-05-22
RS56038B1 (en) 2017-09-29
EP2920192B1 (en) 2017-02-22
CL2015001307A1 (en) 2015-12-11
EP3150616B1 (en) 2017-05-10
DK3235824T3 (en) 2019-05-20
JP2021020919A (en) 2021-02-18
CA2891266C (en) 2020-12-08
IL238792A (en) 2017-09-28
AU2013346515B2 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
US20220033433A1 (en) Process for preparing nucleoside prodrugs
RU2464272C2 (en) Nucleoside aryl phosphoramidates and use thereof as anti-viral agents for treating hepatitus c virus
ES2348741T3 (en) DERIVATIVES OF PHOSPHORAMIDATE OF NUCLEOSID COMPOUNDS FOR USE IN THE TREATMENT OF CANCER.
US20120245029A1 (en) Novel phosph(on)ate- and sulf(on)ate-based phosphate modified nucleosides useful as substrates for polymerases and as antiviral agents
BR112015011155B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING A RP/SP MIXTURE GEMCITABIN-[PHENYL-BENZYLOXY-1-ALANINYL)]-PHOSPHATE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13792965

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2891266

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 238792

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 14442987

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015542357

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12015501090

Country of ref document: PH

Ref document number: MX/A/2015/006195

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015011155

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2013792965

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013792965

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013346515

Country of ref document: AU

Date of ref document: 20131115

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IDP00201503526

Country of ref document: ID

ENP Entry into the national phase

Ref document number: 20157015861

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201590955

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112015011155

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150515